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 H4tera-ac- Acetylation marks on lysines 5,8,12, and 16 in histone H4 
 HAT- Histone acetyl-transferase 
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 PIC- Preinitiation complex 
 Pol II- RNA polymerase II 
 P-TEFb- Positive transcription elongation factor b 
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 SILAC- Stable isotope labeling of amino acids in cell culture 
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Post-translational modifications (PTMs) of histone tails are associated with the regulation 
of transcriptional processes. Patterns of histone modifications mark regions of high or low 
transcriptional activity, and are recognized by “reader proteins”. The reader proteins are 
often transcription factors that recruit chromatin remodelling complexes or enzymes that 
add further modifications to histone tails.  
Genomic enhancer regions, responsible for cell-type specific activation of different genes, 
have been found to exhibit distinct patterns of histone modifications. Active enhancers 
are enriched in acetylation of histone H3 lysine 27 (H3K27ac), a mark which distinguishes 
active from poised and primed enhancers. In this work, we wished to find a protein which 
specifically recognizes this histone modification. 
Bromodomain- containing protein 4 (Brd4) is a transcriptional regulator that is known to 
be involved in the regulation of elongation by RNA polymerase II (Pol II). Brd4 has been 
shown to co-localize with H3K27ac at active enhancers, and was therefore chosen as a 
candidate for selective recognition of H3K27ac.  
Possible binding between the two bromodomains of Brd4 and H3K27ac was investigated 
by histone peptide binding assays, isothermal titration calorimetry (ITC) and surface 
plasmon resonance (SPR). Brd4 bromodomain constructs containing one or both 
bromodomains were engineered, and proteins were expressed and used in binding 
assays. Strong binding between Brd4 bromodomain 1 (BD1) and a H4 peptide acetylated 
at four lysines (H4tetra-ac) was observed, but in contrast to a previously published study, 
no binding between either of the Brd4 bromodomains to H3K27ac was detected in histone 
peptide binding assays and ITC.  
Possible reasons for these discrepancies are discussed and alternative functions for 








Eukaryotic multicellular organisms such as mammals contain a multitude of different cell 
types that have varying morphology, size and function. All the diverse tissues of a grown 
human, from a well-toned bicep muscle to the epithelia lining the intestines, come from 
one single cell; the fertilized egg. They all contain the same genetic material on DNA level 
hence holding the same information for protein synthesis, yet they display very distinct 
phenotypes. 
 In multicellular organisms, differences between cell types are determined by differences 
in their gene-expression profiles, which are represented by the types and amounts of 
proteins and RNA that are present in each cell. Regulation of protein production mainly 
takes place at the transcription level, where the binding and activation of RNA polymerase 
II  (PoI II) at the transcription start site determines if a gene is transcribed or not. The 
association of Pol II at the start of a protein-coding region is determined by its recognition 
of sequence elements within the gene known as promoters. A promoter is a regulatory 
DNA element that is commonly located close to the coding region. Binding and activation 
of Pol II at the promoter is mediated by transcription factors and co-activators, proteins 
that guide and load the polymerase to the promoter, and release it from its promoter-
proximal pausing.   
Comparative genome analyses have revealed that the complexity of organisms does not 
correlate with increased gene number, and relies more on the refinement of gene 
expression regulation. Just under 20,200 protein-coding genes have so far been identified 
in the human genome (UniProtKB, June 2015), which is more than in the fruit fly 
Drosophila melanogaster, but less than in the common grape or the plant Arabidopsis 
thaliana (Pertea and Salzberg, 2010). While the number of genes in the human genome is 
rather low, the estimated number of regulatory DNA sequences is in the range of several 
hundred thousand (Dunham et al., 2012). In eukaryotic cells, and especially in 
multicellular organism, the regulation of transcription by the promoter alone is not 
enough, and an interplay of different regulatory elements, such as silencers, insulators 
and enhancers is needed. In addition, a further level of regulation is imposed on the 
genome at the level of chromatin packing, and through the deposition of post-
translational modifications (PTMs) on DNA-binding proteins called histones (Cheung et 
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al., 2000). A multitude of such modifications exist, and the pattern of different 
modifications in different genome regions has been found to correlate with gene 
expression and repression.  
 
1.1 Structure of chromatin and the nucleosome 
The packaging of eukaryotic DNA has important consequences for the availability of the 
genes within it. Tightly packed DNA is less accessible as a template for transcription, and 
thus transcriptional activators do not only interact with the transcriptional machinery, 
but they also regulate transcription through inducing changes in DNA packaging.  
In eukaryotic cells, long stretches of DNA are managed by coiling them around histone 
proteins, to form a structure know as a nucleosome. Two copies of each of four core 
histones, H2A, H2B, H3 and H4, form an octamer around which 147 bp of DNA is wrapped 
(Luger et al., 1997) (Figure 1.1). Linker DNA, bound by the linker histone H1, serve to join 
the nucleosomes together, forming a structure commonly described as resembling beads 
on a string. Histones are small globular proteins with unstructured N- or C-terminal 
“tails”. They have a high degree of positive charge due to a high content of lysine and 
arginine residues. Electrostatic interactions between the negatively charged phosphate 
backbone of DNA and the many positive amide groups of the histones contribute to the 
tight binding between histones and DNA. The formation of nucleosomes allows the DNA 
to take on folded conformations that reduce its linear length, which is vital to fit the DNA 
into the nucleus in an organized manner. 
The nucleosome is the basic structural and functional unit of chromatin; a dynamic fiber 
of nucleosomes and non-histone proteins.  Chromatin can be packed into higher-order 
structures, mainly depending on the stage of the cell cycle. In metaphase, before cell 
division occurs, the chromatin is packed tightly into chromosomes to equally partition the 
DNA into both daughter cells, but during interphase its structure is more loose and open, 
allowing RNA polymerases to transcribe genes (Raynaud et al., 2014). However, little is 
known about how higher-order chromatin structures are formed. The local structures of 
chromatin during interphase can be divided into two types; euchromatin and 
heterochromatin. Actively transcribed genes are found in euchromatin, while regions that 
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are transcriptionally silent, such as telomers and centromers, are found in the more 






The packaging of DNA into nucleosomes and chromatin limits the accessibility of the DNA, 
making it less available for proteins involved in transcription and replication. To allow 
transcription to occur, nucleosomes must be disrupted and the histones displaced. Post-
translational modification of the protruding N-terminal tails of histone proteins have been 
shown to influence the accessibility of nearby DNA region, both through disruptions in 
contacts between nucleosomes, and through the recruitment of proteins with enzymatic 
functions (Kouzarides, 2007).  
 
 
Figure 1.1: Nucleosome with a selection of post-translational modifications on histone C-
(COOH) and N-(NH2) terminal tails. PTMs placed on histone tails: Ac:-Acetyl; Me-Methyl; Ph-
Phosphoryl; Ub-Ubiquitin. Numbers and upper case letters indicate amino acid residues as follows: 
K-lysine; T-threonine; S-serine; R-arginine.  DNA wrapped around the core histones is shown in light 
grey. (Perla Cota, 2013) 
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1.2 Histone post-translational modifications  
The idea that specific patterns of PTMs on histone proteins can influence gene expression 
is part of the field of epigenetics. The term epigenetics has changed over the years, and is 
still subject of debate. Therefore an operational definition of epigenetics introduced by 
Berger et al.  is used in this thesis: “An epigenetic trait is a stably heritable phenotype 
resulting in changes in a chromosome without alterations in the DNA sequence” (Berger 
et al., 2009). Histone PTMs, are thought to constitute an epigenetic “histone code” (Strahl 
and Allis, 2000), which is passed down to daughter cells and influences which genes 
should be active, and which should be repressed in a specific cell type. In this way the 
modifications provide a way to maintain cellular identity throughout several cell divisions 
(Armstrong, 2014). The PTMs placed on histone tails are often referred to as histone 
marks. 
To date, at least fifteen types of histone PTMs have been identified at 130 different sites 
on the core histone proteins and linker histone (Sadakierska-Chudy and Filip, 2014). 
Some report even higher numbers of possible histone modifications (Tan et al., 2011). 
Histone PTMs are reversible, and are placed on histone tails by histone modification 
enzymes often called “writers” of the histone code, and removed by “erasers”. The most 
widespread and studied histone modifications are acetylation, methylation and 
phosphorylation (Figure 1.1). Acetylation occurs on lysine residues, while methylation is 
found as mono-, di- or trimethyl on lysines, and as mono- or di-methyl on arginines 
(Kouzarides, 2007). Phosphorylations are found on serine, threonine and tyrosine 
residues (Oki et al., 2007). Among other common PTMs are ubiquitination (Zhang, 2003) 
and sumoylation (Shiio and Eisenman, 2003).  
The vast array of possible modifications gives a wide potential for different responses, as 
the marks serve as signaling platforms that govern interactions between chromatin and 
proteins involved in transcription (Strahl and Allis, 2000). Acetylation of lysine residues 
in histone tails has been found to correlate with regions of high gene activity (Grunstein, 
1997), while methylation is found in both active and repressed regions. Lysine 
trimethylation (Kme3) at histone H3 lysine 4 (H3K4), H3K36 and H3K79 are enriched in 
gene-coding regions and are involved in gene expression (Kouzarides, 2000; Strahl et al., 
1999). Methylation of H3K9 and H3K27, however, are associated with repression of gene 
expression, and are found in heterochromatin and heterochromatin-boundary regions 
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(Trojer and Reinberg, 2007). Actively transcribed regions are marked by hyper-
acetylation of histones H3 and H4, which is thought to disrupt the chromatin structure 
and allow transcriptional factors to access the DNA (Struhl, 1998). The addition of an 
acetyl group on a lysine residue removes the positive charge of the ε- nitrogen (Figure 
1.2), which can decrease the net positive charge of the basic histone tails and thus 
decrease its electrostatic interactions with the negative DNA backbone, and to other 
nucleosomes (Kouzarides, 2000). Acetylation marks are placed on lysines by the action of 
histone acetyltransferases/lysine acetyltransferases (HATs/KATs) and removed by 
histone deacetylases (HDACs) (Shahbazian and Grunstein, 2007). Proteins recruited to 
histone modifications bind though specific domains which are often termed as “readers” 
of the histone code. Different modifications recruit a different set of proteins which have 
diverse functions on chromatin composition and gene expression of nearby genomic 
regions. Histone acetylations are non-randomly placed in chromatin, and particular 




The differences between cell types arise from differential gene expression. Some genes 
are actively transcribed in one cell-line, but repressed in another and vice versa. In 
metazoans, the regulation of transcription is not only limited to the promoter region, but 
is distributed among a complex set of distal regulatory sequence elements. Enhancers are 
one class of such regulatory elements and have been found to be the major determinant 
of cell type specificity (Bulger and Groudine, 2010; Heintzman et al., 2009). Enhancers are 
defined as DNA sequence elements that when linked in cis to a promoter, can increase its 
Figure 1.2: Chemical structures of lysine and 
acetyl-lysine. Acetylation of lysine residues 
happens through the placement of an acetyl-group 
on the ε-nitrogen by the actions of histone 
acetyltransferases (HATs), and is removed by 
histone deacetylases (HDACs). Waved lines 
represent connections to the rest of the 
polypeptide chain. 
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activity regardless of orientation. The properties of enhancer elements were first 
described for a viral SV40 sequence that enhanced the transcription of a hemoglobin β1 
gene introduced into HeLa cells, (Banerji et al., 1981). Target promoters can be located 
thousands of base pairs either upstream of downstream from the enhancers that control 
them, and he median distance between enhancer and promoter has been estimated to be 
125 kb, with the majority of enhancers being located within 500 kb of the promoter they 
regulate (Jin et al., 2013). There are however examples of enhancers that act from even 
longer distances (Amano et al., 2009).  
 
Enhancers are comprised of clusters of recognition sequences for cell-specific 
transcription factors, and are typically a few hundred base pairs in length. Enhancers, as 
well as other regulatory elements, exhibit hypersensitivity for DNaseI digestion. This 
sensitivity has been attributed to the exclusion of nucleosomes in the enhancer region, 
due to binding of transcription factors, which increases DNA accessibility at particular 
sites (Elgin, 1988). Studies of genome-wide DNaseI hypersensitivity and transcription 
factor binding sites have suggested that a large portion of enhancers are cell-type specific 
(Xi et al., 2007), and that only a small fraction are active in any given cell line. This is 
consistent with their role as determinants of cell type-specific gene expression. The 
ENCODE consortium has identified approximately 400,000 enhancer-like elements in the 
human genome (Dunham et al., 2012), while the FANTOM consortium has reported 
43,000 active enhancer candidates (Andersson et al., 2014). Active enhancers increase 
transcription of genes by interacting with its paired promoter. The mechanisms of how 
this occurs are however still very much under debate. The current  view is that enhancers 
influence promoter activity through direct encounters in three-dimensional space, 
through the action of DNA-looping (Figure 1.3) (Bulger and Groudine, 1999). The 
enhancer brings several needed transcription factors and co-activators to the promoter, 
which in turn either promote assembly of the preinitiation complex (PIC) at the promoter, 
or release of the paused Pol II downstream of the promoter which drives the transition 
from initiation to elongation (Plank and Dean, 2014).  Promoters that are engaged in 
looping have been shown to have significantly increased levels of transcription (Rao et al., 
2014). Interestingly, studies in Drosophila have revealed that three-dimensional 
interactions between enhancers and promoters do not change during development, 
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which indicates that transcription is activated by additional signals after DNA looping has 
brought the enhancer and promoter into proximity of each other (Ghavi-Helm et al., 
2014). This type of pre-existing loops have also been observed in mouse and human cells 
(Jin et al., 2013; de Laat and Duboule, 2013). In the light of these findings, one hypothesis 
of how enhancer-mediated gene expression is activated is that after enhancer –promoter 
looping, Pol II is recruited but paused downstream of the promoter. The recruitment of 
transcription factors, or even possibly additional enhancers then triggers the pause-






Enhancers have been found to be able to control more than one gene, and recent studies 
have indicated that active enhancers interact with approximately two promoters on 
average, while active promoters were found to have contacts with 4-5 enhancer-like 
elements on average (Jin et al., 2013). These findings suggest that it is the combinatorial 
control of several enhancers on a promoter that determines a gene’s expression in a 
specific cell type. Most enhancer-promoter interactions occur in distinct chromatin 
domains known as topological association domains (Dixon et al., 2012). These domains 
on average contain 5-10 genes and a few hundred enhancers (Jin et al., 2013). Even though 
Figure 1.3: Enhancer-promoter interactions. Enhancers interact with their cognate promoters 
through direct interactions facilitated by DNA looping. Enhancers are activated by the binding of linage-
dependent (LDTF) and- signal-dependent (SDTF) transcription factors, and the presence of an acetyl 
modification on histone H3 lysine 27 (H3K27ac). Enhancers are marked by monomethylation of lysine 
4 (H3K4me1), while promoters are found to exhibit trimethylation of lysine 4 (H3K4Me3). Elongation 
by Pol II occurs at both active enhancers and promoters. For simplicity, only one Pol II is shown.  
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information about enhancer-promoter interactions is accumulating, an important 
question still remains unanswered; how do enhancers interact with their cognate 
promoters specifically, and what proteins are involved in these interactions? 
 
1.4 Histone modifications and enhancer activation 
 Genome wide studies have suggested that enhancers exhibit a characteristic chromatin 
signature in the form of histone PTMs and also specific transcription factor binding. The 
modifications that are displayed can be used to distinguish between different enhancer  
states (Ernst and Kellis, 2010). Enhancer states can be classified as inactive, primed, 
poised or active. Inactive enhancers, buried in compact chromatin, are not bound by 
transcription factors and show no typical pattern of histone modifications. Primed 
enhancers are bound by lineage dependent sequence-specific transcription factors, 
making them ready for subsequent activation by binding of signal dependent factors 
(Ernst and Kellis, 2010). Primed enhancer regions are marked by histone H3 lysine 4 
mono-methylation (H3K4me1) and di-methylation (H3K4me2) (Heintzman et al., 2007). 
Poised enhancers are similar to primed enhancers, but are in addition marked with a 
repressive H3K27me3 mark (Rada-Iglesias et al., 2011). In poised enhancers, histone 
deacetylase (HDAC)- containing complexes maintain histones in a repressed deacetylated 
state, while nucleosome remodeling complexes (NRCs) keep the region nucleosome-free 
(Reviewed in Heinz et al., 2015). Methyltransferases which maintain H3K4 and H3K27 
methyaltion are also present at poised enhancers. The poised state is most commonly 
found in embryonic stem cells, and is located near key early developmental genes (Rada-
Iglesias et al., 2011).  
Active enhancers share many of the features of poised enhancers, but are able to drive 
gene expression. Acetylation, rather than trimethyaltion of H3K27 is one of the hallmarks 
of active enhancers (Creyghton et al., 2010), and is placed on histone H3 by the HAT p300 
and CREB-binding protein CBP (Tie et al., 2009). Poised enhancers become active during 
differentiation, when the trimethyaltion mark (H3K27me3) is exchanged for the 
acetylation mark H3K27ac (Rada-Iglesias et al., 2011). Other important features 
associated with active enhancers is the presence of actively transcribing Pol II in the 
company of the Mediator complex (de Santa et al., 2010). Pol II transcription at active 
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enhancers is bidirectional, and produces enhancer RNA (eRNA). eRNAs are short RNA 
sequences that are not spliced, and have short half-lives (Kim et al., 2010). Pol II 
recruitment to enhancers and changes in eRNA expression are highly correlated with the 
expression of nearby genes, suggesting that the transcription of eRNA at enhancers is 
important for enhancer function (Reviewed in Lam et al., 2014) .   
 
The available evidence suggests that enhancers are marked with H3K4me1 as a general 
mark priming them for activation, and that further modification with H3K27ac distinguish 
them as active (Rada-Iglesias et al., 2011). The presence of H3K4me1 is not unique to 
enhancers, and is also found in 5’ portions of transcribed genes, and in broad regions 
around enhancer elements (Calo and Wysocka, 2013). Its presence is, however, often 
found to precede nucleosome depletion, and deposition of H3K27ac. Acetylation of H3K27 
is almost exclusively found in regions that have already been marked by H3K4me1 (Bonn 
et al., 2012), adding weight to the hypothesis that H3K4me1 primes enhancers for later 
activation. It is important to note that H3K27 acetylation is not exclusive to enhancers, as 
active promoters are also found to exhibit this mark (Shlyueva et al., 2014). Although 
chromatin signatures can be used to identify enhancer position and activity, direct 
evidence showing the role of enhancer chromatin modifications in vivo is still lacking.  
Finding a protein that specifically recognizes the H3K27 acetylation mark might cast some 
light on how this modification contributes to the activation of enhancers, and to 
subsequent enhancer-facilitated gene transcription. 
 
1.5 Acetylation- recognition domains 
The most well-known acetyl-lysine recognition domain is the bromodomain. The human 
genome encodes 61 bromodomains in 46 different proteins. Many bromodomain-
containing proteins are multi-modular and can harbor catalytic domains, protein-
interaction domains and even more than one bromodomain. (Filippakopoulos et al. 2012). 
Although there are large sequence variations among different bromodomains, they all 
share a conserved fold of a left-handed bundle of four α- helices linked by loop regions of 
variable length (Figure 1.4.A). The helices are denoted αZ, αA, αB, αC, while the linking loop 
regions are named ZA and BC. The long loop between helices αZ and αA, (the ZA loop) is 
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packed together with a loop connecting αB and αC (BC loop) to form a deep hydrophobic 
pocket at one end of the four-helix bundle (Figure 1.4.B). (Dhalluin et al., 1999) It is this 
hydrophobic cavity that binds the acetyl-lysine side chain through hydrogen bonding to a 
conserved asparagine located in the BC loop.  Only a small number of lysine acetylation 
marks have been identified to specifically interact with individual bromodomains, and 
they often exhibit low affinities (Filippakopoulos et al., 2012).  
 
Bromodomains were long thought to be the only domains able to specifically recognize 
acetyl-lysine motifs, but recently other domains have been found to exhibit specificity to 
acetyl-lysine histone marks as well. Some tandem plant homeodomain (PHD) zinc fingers, 
and the plecstrin-homology (PH) domain of yeast chaperone protein Rtt106 have been 
shown to bind histone H3 in an acetylation-sensitive manner (Ali et al., 2012; Su et al., 
2012). A newly discovered domain called YEATS, named after its five founding domain-
containing proteins Yaf9, ENL, AF9, Taf4 and Sas5, has also been reported to bind acetyl-
lysine modifications (Li et al., 2014). The YEATS domain of AF9, a component of the super 
elongation complex (SEC) was found to bind acetylated histone H3, with a preference for 
H3K9 acetylation. The affinity of AF9 YEATS binding to H3K9ac was found to be much 







Figure 1.4: Three dimensional structure of bromodomain 1 (BD1) of Brd4. A: The conserved 
bromodomain fold of Brd4 bromodomain 1. B: The ZA and BC loops are packed together to form a 
hydrophobic binding pocked for acetyl-lysine. The figure shows an overlay of three doubly 
acetylated histone peptides bound in the hydrophobic pocked. (Filippakopoulos et al. 2012) 
A B 
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1.6 Bromodomain containing protein 4 (Brd4) 
Brd4 is a bromodomain containing protein that is part of the bromodomain and 
extraterminal domain (BET) family. The BET family is conserved from yeast to mammals, 
and includes mammalian Brd2, Brd3, Brd4 and BrdT. The BET proteins are adaptor 
proteins that are involved in in the regulation of transcription by Pol II (Florence and 
Faller, 2001). The BET proteins all contain two N-terminal bromodomains, BD1 and BD2, 
which recognize acetylated lysine residues on histone tails and other proteins (Figure 
1.5). They also contain a conserved and unique extraterminal domain (ET-domain) which 
is involved in interactions with proteins such as histone modifiers and NRCs (Liu et al., 
2013; Rahman et al., 2011). The bromodomains of the BET-family are highly conserved, 
and share similar hydrophobic binding pockets for the binding of acetylated lysines. The 
two bromodomains, BD1 and BD2, however exhibit less similarity within the same 
protein than to their homologous domains in other BET-family members (44% to 75% 
identity) (Nakamura et al., 2007). Brd4 is the most widely studied of the BET- proteins, as 
it is a therapeutic target in several cancers (Shi and Vakoc, 2014). Brd4 is ubiquitously 
expressed in mammals, and knockout of Brd4 in mice has been shown to lead to early 
embryonic lethality (Houzelstein et al., 2002).  
 
 Three distinct human Brd4 isoforms have been identified, A, B and C. The three differ only 
in the C-terminal region (CTD), where isoforms B and C either completely lack this region 
(B) or have a shorter unique version (C). Isoform A, hereafter referred to as Brd4, is 
involved in transcription by Pol II, through interactions with different proteins and 
complexes, such as the mediator complex (Wu and Chiang, 2007), and the positive 
transcription elongation factor b (P-TEFb) (Moon et al., 2005). P-TEFb is a dimer of the 
cyclin dependent kinase Cdk9 and one of its regulatory subunits cyclin T1, T2 or K. This 
complex promotes transcriptional elongation by Pol II by releasing it from its pausing at 
the promoter-proximal region through phosphorylation of Pol II’s C-terminal domain, and 
of Pol II-associated negative regulatory factors (Peng et al., 1998). P-TEFb is under tight 
regulation, and the majority of inactive P-TEFb is sequestered in a small ribonucloprotein 
complex, which represses its kinase activity (Prasanth et al., 2010). Brd4 binds to P-TEFb 
through a two-pronged binding, where a P-TEFb interaction domain (PID) in its C-
terminal region binds to Cdk9, while the second bromodomain, BD2, binds a set of 
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acetylated lysine residues in cyclin T1. (Schröder et al., 2012). Brd4-binding to P-TEFb 
releases it from its repressive factors, and recruits it to promoter regions in a 
bromodomain-mediated fashion (Figure 1.6). (Moon et al., 2005). Less is known about 
Brd4’s interactions with the Mediator complex, but the two have been shown to occupy 
many of the same regions across the genome (Lovén et al., 2013). In addition, the first 
identification of Brd4 was with the original purification of the human Mediator complex 





Brd4 has also been implicated in activation of transcription independently from P-TEFb, 
through the recruitment of NSD3, a histone methyltransferase that methylates H3K36; a 
modification enriched in transcriptionally active regions (Rahman et al., 2011). This 
recruitment occurs through the ET domain of Brd4.  
Chromatin immunoprecipitation coupled with DNA- sequencing (ChiP-seq) has been 
utilized to analyze the genome-wide chromatin occupancy of Brd4. In agreement with its 
role as a transcriptional regulator, Brd4 has been found at essentially all active promoters, 
but also at a significant portion of active enhancers in various normal and transformed 
cell types (Lovén et al., 2013; Zhang et al., 2012). In these types of experiments, active 
enhancer regions are defined by their enrichment of H3K4me1 and H3K27ac, an 
acetylation mark that as described above, is one of the hallmarks of active enhancers.  
Particularly high Brd4-occupancy is found in large clustered enhancers called super-
enhancers, where the level of H3K27ac is higher than in typical enhancers (Lovén et al., 
2013). Super-enhancers regulate the expression of cell-fate determining genes, and are 
bound by high levels of master transcription factors and the Mediator complex (Whyte et 
al., 2013). While Brd2 and Brd3, other BET-family proteins, are found mostly at 
promoters, higher levels of Brd4 are found at a selection of enhancers than at promoters 
(Engelen et al., 2015).   
Figure 1.5: Brd4 domain organization. Brd4 is a 1362 amino acids long protein with two N-terminal 
bromodomains, BD1 and BD2, an extraterminal domain (ET) and a C-terminal P-TEFb interaction 
domain (CTD/PID). In addition, it has an N-terminal cluster of phosphorylation sites (NPS) which is 
important in its regulation, and a basic residue enriched interaction domain (BID). 







Brd4 has been found to facilitate elongation of eRNA at enhancers in a manner that is 
bromodomain-dependent.  This was discovered when the addition of JQ1, a specific BET-
bromodomain inhibitor, was found to antagonize eRNA synthesis at Brd4-associated 
enhancers (Kanno et al., 2014). Evidence has also been put forth suggesting that Brd4 
interacts with the arginine demethylase Jmjd6 and P-TEFb to regulate pause-release of 
Pol II at a large number of genes. This is proposed to occur through the binding of Brd4 
and Jmjd6 to distal anti-pause enhancers leading to the release of paused Pol II at cognate 
promoters through looping and interactions with P-TEFb (Liu et al., 2013).  
As it has been suggested that Brd4 is recruited to enhancers in a manner dependent on its 
bromodomains, and that it has been found to co-localize with H3K27ac, Brd4 arises as a 
candidate for H3K27ac recognition.   
Figure 1.6: Model of Brd4-mediated Pol II pause-release. A: Brd4 binds to P-TEFb through its P-TEFb 
interaction domain, PID, and recruits it to acetylated chromatin at enhancers and promoters. Brd4 binds 
acetylated lysines on histone H3 and H4 tails. B: The kinase component of P-TEFb phosphorylates serine 
residues in the C-terminal tail of Pol II, and negative factors bound to Pol II (not shown). C: 
Phosphorylation of the CTD and removal of negative factors leads to pause-release of Pol II, which 
continues the elongation of eRNA at enhancers, and mRNA at gene bodies. Only one Pol II is shown for 
transcription at enhancers and promoters. 
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1.7 Aim and strategy of the study 
Our research group is investigating the role of histone acetylation in enhancer function 
and, in particular, the role of H3K27ac which is enriched in enhancer chromatin. While 
others in the group are searching for H3K27ac-binding proteins by pull-down 
experiments and mass-spectrometry, the purpose of this project has been to investigate 
Brd4 as a candidate H3K27ac-binding protein. It had been previously reported that Brd4 
co-localize with H3K27ac marks in enhancer chromatin (Lovén et al., 2013). Furthermore, 
a medium through-put SPOT assay with all human bromodomains had identified BD1 of 
Brd4 as a candidate H3K27ac-binder (Filippakopoulos et al., 2012).  
On this basis, the aim of this study has been to confirm the binding between Brd4 BD1 and 
H3K27ac with quantitative methods and prepare for further functional studies. 
Three in vitro binding assays were chosen for this work: i) histone peptide binding assays, 
which would give information of binding specificity; ii) ITC and iii) SPR which would both 
















Table 2.1: Chemicals 
Name Abbreviation/formula Supplier 
2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid 
HEPES Sigma Life Science 
Acrylamide/Bis-acrylamide 37.5:1 
(30%) 
C3H5NO/C7H10N2O2 Sigma Life Science 
Ammonium persulfate  APS Merck 
Ampicillin Amp Bristol-Myers Squibb 
Agar-agar  Merck 
Agarose  Sigma L.S 
Boric acid H3BO3 Merck 
Bovine serum albumin BSA Sigma 
Bromophenol blue BPB Sigma 
Calcium chloride CaCl2 Merck 
Chloroform CHCl3 Sigma 
Deoxyribonucleotide triphosphate 
(ATP, TTP, CTP, GTP) 
dNTPs Takara 
Dimethyl sulfoxide DMSO Sigma 
Dithiothreitol DTT Sigma 
Disodium hydrogen phosphate Na2HPO4 • 2H2O Merck 
EDTA-free protease inhibitor 
cocktail 
 Roche Diagnostics 
Ethanol EtOH Kemethyl 
Ethidium bromide EtBr Sigma 
Ethylenediaminetetraacetic acid EDTA Merck 
Glycerol C3H4O3 Sigma-Aldrich 
Hydrochloric acid HCl Sigma-Aldrich 
Imidazole (1H-Imidazole) C3H4N2 Merck 






Magnesium chloride MgCl2 Merck 







Peptone  Merck 
Polyethylene sorbitan 
monolaurate 
Tween® 20 Sigma-Aldrich 
Potassium chloride KCl Merck 
Skimmed milk powder  Merck 
Sodium acetate CH3COONa Merck 
Sodium chloride NaCl Sigma-Aldrich 
Sodium dodecyl sulfate SDS Bio-Rad 
Sodium hydroxide NaOH Merck 




Triton X-100 (C2H4O)4C14H220 Sigma 








   2. Materials 
18 
 
Table 2.2: Pre-prepared commercial buffers and reagents 
Name Purpose Supplier 
Imperial™ Protein Stain SDS-PAAG staining Thermo Scientific 
BigDye® v.3.1 DNA sequencing Applied Biosystems 
Running gel buffer (1 M 
Tris-HCl pH 8.8) 
SDS-PAAG Bio-Rad 
Stracking gel buffer (0.5 M 
Tris-HCl pH 6.8) 
SDS-PAAG Bio-Rad 
TG, Transfer buffer Immunoblotting Bio-Rad 
TGS, Running buffer SDS-PAGE Bio-Rad 
TRI Reagent® Trizol RNA extraction Sigma Life Science 
 
Table 2.3: Antibodies, source and working dilutions 
Name Origin Dilution Type Supplier 
Anti-GST Rabbit 1:10,000 Polyclonal Sigma 
ECL Anti-rabbit (HRP-conjugated) Donkey 1:10,000 Secondary GE Healthcare 
 
Table 2.4: Bacterial strains 
Strain Purpose Supplier 
Escherichia coli BL12-CodonPlus®-RIL Protein expression Agilent 
Escherichia coli M15 Protein expression Sigma-Aldrich 
Escherichia coli XL1-blue DNA amplification Agilent 
 
Table 2.5: Commercial kits 
Kit Use Supplier 
Amersham ECL Plus Western 
Blotting Detection Reagents 
Immunoblot detection GE healthcare 
Nucleospin® Gel and PCR  
clean-up 
DNA purification Macherey-Nagel 
Nucleospin® Plasmid Miniprep plasmid purification Macherey-Nagel 
Nucleobond® Xtra Midi Midiprep plasmid purification Macherey-Nagel 
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Table 2.6: Enzymes for cDNA syntehsis and cloning 
Name  Supplier 
Go-Taq flexi polymerase  Promega 
Phusion™ Hot Start II DNA Polymerase  Thermo Scientific 
M-MuLV reverse transcriptase  Thermo Scientific 
T4 DNA ligase  New England Biolabs 
 
Table 2.7: Plasmids 
Name Antibiotic 
resistance 
Protein product tag Reference/supplier 
pSXG Ampicillin N-terminal GST Ragvin et al., 2004 




Ampicillin N-terminal GST Ragvin et al., 2004 
 
 
Table 2.8: Protein molecular weight and DNA size markers 
Name Purpose Supplier 
2-log DNA ladder DNA size marker New England Biolabs 
Precision Plus Protein Dual Color 
Standard 
Protein size marker Bio-Rad 
 
Table 2.9: Restriction enzymes  
Name Recognition sequence and cleavage site Supplier 
BamHI 5’ G|GATCC 3’ Takara 
EcoRI 5’ G|AATTC 3’ Takara 
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Table 2.10: Consumables 
Name Purpose Supplier 
PD-10 desalting column Buffer exchange GE Healthcare 
PVDF Hybond-P membranes Immunoblotting Amersham 
Slide-A-Lyzer® Dialysis cassettes 
(3.500 MWCO) 
Dialysis Thermo Scientific 
Slide-A-Lyzer® MINI units (3.500 
MWCO) 
 
Dialysis Thermo Scientific 
Table 2.11: Resins used for protein purification and peptide binding assays 
Name Purpose Supplier 
Glutathione Sepharose 4B resin GST-protein purification GE Healthcare 
Ni-NTA agarose resin IMAC purification Qiagen GmbH 
Streptavidin Sepharose™ high 
performance 
Histone peptide pulldowns GE Healthcare 
 
Table 2.12: DNA primers 
Primer  Primer sequence, 5’-3’ Purpose 
BRD4-FL-F ATAGGATCCTATCTGCGGAGAGCGGCCCT Cloning 
BRD4-FL-R ATACCTAGGCGCTCAGAAAAGATTTTCTTCAAAT Cloning 
BD1-pSXG-F AATTAGAATTCAACCCCCCGCCCCCAG Cloning 
BD1-pSXG-R AATGGATCCTCATTCTTCTGTGGGTAGCTCATTTATTTTTTG Cloning 
BD2-pSXG-F AATTAGAATTCAAGGACGTGCCCGACTCTC Cloning 
BD2-pSXG-R AATGGATCCTCACTCGTCCGGCATCTTGGC Cloning 
BD1-pQE30-F AATGGATCCAACCCCCCGCCCCCAG Cloning 
BD1-pQE30-R AATAAAGCTTTCATTCTTCTGTGGGTAGCTCATTTATTTTTTG Cloning 
BD2-pQE30-F AATGGATCCAAGGACGTGCCCGACTCTC Cloning 
BD2-pQE30-R AATAAAGCTTTCACTCGTCCGGCATCTTGGC Cloning 
BD1-s-F AATTAGAATTCGTGCTCAAGACACTATGGAAAC Cloning 
BD1-s-R AATGGATCCTTAAGCTTCTGCCATTAAGACTATGT Cloning 
BD2-s-F AATTAGAATTCCGAGATGTTTGCCAAGAAGCACG Cloning 
BD2-s-R AATGGATCCTTACTTGCGGGCCATGGCCAC Cloning 
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BD1-seq-F CCCCCAGAGACCTCCAAC Sequencing 
BD1-seq-R AGCTTTCATTCTGTGGGTAGCTC Sequencing 
BD2-seq-F AAGGACGTGCCCGACTCTCA Sequencing 
BD2-seq-R CTCGTCCGGCATCTTGGCAAA Sequencing 
3PGEX CCGGGAGCTGCATGTGTCAGAGG Sequencing 
5PGEX GGGCTGGCAAGCCACGTTTGGTG Sequencing 
pQE30-seq-F AGGCCCTTTCGTCTTCACCTC Sequencing 
pQE30-seq-R CCATAAAAAACGCCCGGCGG Sequencing 
 
Table 2.13: Peptides for ITC from LifeTein 












4*Lys(Ac) 1490 2628.04 
*Calculated with the online resource ProtParam 
 
Table 2.14: Biotinylated peptides for histone peptide binding assays from 
Biosyntan 
Name Sequence Modification M.W (Da) 
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Table 2.15: Instruments and equipment 
Name Use Manufacturer 
Allegra X-15 R Centrifuge Centrifugation Beckman Coulter 
Avanti J-26 XP Centrifuge Centrifugation Beckman Coulter 
Biacore T100, T200 
sensitivity enhanced 
Surface plasmon resonance Biacore (GE Healthcare) 
ChemiDoc™ XRS+ Immunoblot imaging Bio-Rad 
GelDoc™ EZ Gel imaging Bio-Rad 
Nano ITC Isothermal titration 
calorimetry 
TA Instruments 
Trans-Blot® Turbo™ Immunobloting Bio-Rad 
Zetasizer Nano ZS Dynamic light scattering Malvern 
Zen2112 quartz cuvette Dynamic light scattering Malvern 
Ækta explorer Size-exclusion 
chromatography 
GE Healthcare 
Superdex 75 HiLoad™ 





Table 2.16: Software 
Name Use Developer/Website 
Biacore T200 Control 
Software v.2 
SPR experiment control Biacore (GE Healthcare) 
Biacore T200 
Evaluation Softwave v.1 
SPR data analysis Biacore (GE Healthcare) 
Clustal Omega Multiple sequence alignment http://www.ebi.ac.uk/Tool
s/msa/clustalo/ 
Imagelab v SDS-gel and immunoblot 
visualization 
Bio-Rad 
ITCRun v.2 ITC experiment control TA Instruments 
NanoAnlayze v2.4.1 ITC data analysis TA Instruments 
ND-1000 Protein/DNA concentration 
determination 
Saveen-Werner 
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OligoCalc Oligo Tm calculator http://www.basic.northwes
tern.edu/biotools/oligocalc.
html 




Generation of plasmid maps GSL Biotech LLC 
Unicorn 5.2 Ækta control software GE Healthcare 
 
 
2.1 Prepared buffers and solutions 
2.1.1: Solutions for agarose gel electrophoresis 
 
Table 2.17: TBE buffer    Table 2.18: 6x DNA loading buffer 
Chemicals Concentrations  Chemicals Concentrations 
Tris base 100 mM  Tris-HCl 10 mM 
Boric acid 90 mM  Bromophenol blue 0.03% (w/v) 
EDTA 1 mM  Glycerol 60% (v/v) 
   EDTA 60 mM 
  
Table 2.19: Agarose gel 
Chemicals Concentrations 
Agarose in 0.5x TBE 1-2 % (w/v) 
Ethidium bromide 0.5 µg/ml 
 
2.1.2 Media for cultivation of bacteria 
 
Table 2.20: Lysogeny Broth (LB medium)         Table 2.21: LB-agar  
Chemicals Concentrations  Chemicals Concentrations 
Tryptone 10 g/l  Tryptone 10 g/l 
NaCl 10 g/l  NaCl 10 g/l 
Yeast extract 5 g/l  Yeast extract 5 g/l 
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   Agar 15 g/l 
 
2.1.3 Buffers and solutions for SDS-PAGE and immunoblotting 
 
Table 2.22: SDS- polyacrylamide resolving gel 
Components Final Concentrations Stock solution 
Acrylamide/bisacrylamide 12-15% (w/v) 30%, 37.5:1 
Tris-HCl pH 8.8  390 mM 1.5 M pH 8.8 
SDS 0.1% (w/v) 20% (w/v) 
APS 0.1% (w/v) 10% (w/v) 
TEMED 0.04 % (v/v) 99% (v/v) 
 
 
Table 2.23: SDS-Polyacrylamide stacking gel 
Components Final Concentrations Stock solution 
Acrylamide/bisacrylamide 3.4% (w/v) 30%, 37.5:1 
Tris-HCl pH 6.8 172 mM 0.5 M pH 6.8 
SDS 0.1% (w/v) 20% (w/v) 
APS 0.1% (w/v) 10% (w/v) 
TEMED 0.08% (w/v) 99% (v/v) 
   
 
Table 2.24: 1x SDS running buffer  Table 2.25: 1x Transfer buffer 
Chemicals Concentrations  Chemicals Concentrations 
Tris-HCl pH 8.3 25 mM  Tris-HCl pH 8.3 25 mM 
Glycine 192 mM  Glycine 192 mM 
SDS 0.1 % (w/v)  Methanol 20 % (v/v) 









Table 2.26: 2x SDS sample buffer   Table 2.27: 1x PBS (tween) 
Chemicals Concentrations  Chemicals Concentrations 
Tris-HCl pH 6.8 100 mM  Nacl 137 mM 
SDS 4% (w/v)  KCl 2.7 mM 
Glycerol 20% (v/v)  Na2HPO4 4.3 mM 
DTT 200 mM  KH2PO4 1.47 mM 
Bromophenol 
blue 
0.2% (w/v)  (Tween-20) (0.05 %) 
 
 
2.1.4 Buffers and solutions for GST- fusion protein purification 
 
Table 2.28: GST-purification lysis buffer            Table 2.29: Glutathione elution buffer 
Components Concentrations  Chemicals Concentrations 
Tris-HCl pH 7.5 250 mM  Reduced 
Glutathione 
15 µM 
NaCl 50 mM  Tris-HCl pH 8.0 50 mM 
DTT 1 mM  






2.1.5 Buffers and solutions for IMAC protein purification 
 
Table 2.30: IMAC lysis buffer 
Chemicals Concentrations 
Tris-HCl pH 7.0 50 mM 
NaCl 300 mM 
Imidazole 20 mM 
Triton-x 100 0.2 % (v/v) 
EDTA free protease inhibitor 1x 
DTT 1 mM 




Table 2.31: IMAC wash buffer      Table 2.32: IMAC elution buffer 
Chemicals Concentrations  Chemicals Concentrations 
Tris-HCl pH 7.0 50 mM  Tris-HCl pH 7.0 50 mM 
NaCl 300 mM  NaCl 300 mM 
Imidazole 20 mM  Imidazole 500 mM 





2.1.6 Buffers for protein- peptide binding studies 
 
Table 2.33: Shi buffer      Table 2.34: ITC T7.5/T8.5 buffer  
Chemicals Concentrations  Chemicals Concentrations 
Tris-HCl pH 7.5 50 mM  Tris-HCl pH 
7.5/8.5 
50 mM 
NaCl 300 mM  NaCl 150 mM 













3.1 Construction of expression vectors for Brd4 bromodomains 
3.1.1 Primer design 
Primers were designed for amplification of the two bromodomains of human Brd4, BD1 
and BD2 separately and together. Primers for two different sets of Brd4 constructs were 
created, one set which included only the core bromodomain sequences with five flanking 
residues on either side (BD1-s/BD2-s), and one where BET-family-specific flanking 
sequences were included (BD2/BD2) (Refer to figure 4.1 for construct sequences). 
Domain boundaries were based on sequences retrieved from UniProtKB (BRD4_HUMAN). 
Primers were designed with restriction sites for cloning into two different vectors, pSXG 
and pQE30 (Appendix 1). Sequencing primers specific for the Brd4 bromodomains and 
the pQE30 vector were also designed (Table 2.12). The online resource OligoCalc was 
used to calculate the melting temperature of designed primers. 
The pSXG vector has an integrated N-terminal Glutathione S-transferase (GST) coding 
sequence, which upon expression produces a GST-tagged fusion protein. The fusion 
proteins can be purified with affinity chromatography. Inclusion of a GST tag can also 
improve the solubility of recombinant proteins. pQE30 encodes six N-terminal histidines 
(His-tag). His-tagged proteins can be purified through immobilized metal affinity 
chromatography (IMAC).  
3.1.2 RNA extraction and cDNA synthesis 
Total RNA was extracted from HeLa S3 cells using the trizol TRI Reagent®. A HeLa cell 
pellet from two 80% confluent 10 cm plates was homogenized by pipetting and 
incubation for 5 min at RT in 1 ml TRI Reagent®. 0.2 ml chloroform was added to the 
homogenized sample, and the solution was incubated for 3 min, before centrifugation at 
12 000 g for 10 min. The upper aqueous phase was collected, and the RNA was purified 
by precipitation with 0.5 ml 100% isopropanol. The RNA pellet was washed with 1 ml 
75% ethanol, air dried and resuspended in 30 µl RNase-free water. To achieve greater 
purity, RNA was subjected to ethanol precipitation with 0.1 volume of 3 M sodium acetate 
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pH 5.2 and 2.2 volumes 100% ethanol at -20 °C for 20 min. The RNA pellet was washed 
with 70% ethanol, air dried and dissolved in 50 µl RNase-free water. 
First-strand cDNA synthesis from total RNA was performed with M-MuLV reverse 
transcriptase and oligo(dT) oligomers. A sample of 0.5-1 µg total RNA was mixed with 0.5 
µg oligo(dT), 1X RT reaction buffer, 10 mM dNTPs, 40 U M-MuLV reverse transcriptase 
and dH2O to a final volume of 25 µl. The reaction took place at 37 °C for 60 minutes, and 
was stopped by heat inactivation of the enzyme at 70 °C for 10 min.  
3.1.3 PCR amplification of Brd4 bromodomains 
PCR was carried out with cDNA template prepared as described above, and primers 
shown in table 2.12.  
Table 3.1: Thermocycler program for the amplification of Brd4 bromodomains 
Step Temperature Time Cycles 
Initial denaturation 98 °C 5 minutes  1 
Denaturation 98 °C 10 seconds  
Annealing Tm 30 seconds 30 
Elongation 72 °C 1 minute  
Final elongation 72 °C 5 minutes 1 
 
PCR was performed as shown in table 3.1, in 50 a µl reaction volume with final 
concentrations of 1X  phusion HF reaction buffer, 200 µM dNTPs, 0.5 µM primers, 1 µl 
template cDNA, 3% DMSO and 0.02 U/µl Phusion™ Hot Start II DNA Polymerase. 
 
3.1.4 Cloning of Brd4 bromodomains into expression vectors 
PCR products were purified from agarose gel using NucleoSpin® Gel and PCR Clean-Up 
Kit from, following the manufacturer’s instructions. A 1% agarose gel was used for the 
purification of BD2 and BD1+BD2 PCR products, while a 2% gel was used for purification 
of BD1. The purified PCR products were subjected to restriction digestion by appropriate 
restriction enzyme. The pSXG vector and the PCR products to be inserted in it were 
digested with BamHI and EcoRI, while pQE30 and its inserts were digested with BamHI 
and HindIII. PCR product digestion was carried out as a double digestion in a 50 µl 
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reaction volume with 1X buffer K, 0.3 U/µl restriction enzymes and 10 ng/µl insert DNA. 
The reaction was carried out at 37 ° for one hour, and stopped by heat inactivation at 70 
°C for 10 minutes. The digested DNA inserts were purified using Nucleospin® Gel and PCR 
clean-up column. pSXG and pQE30 plasmids were linearized by restriction in a 50 µl 
reaction with 1X buffer K, 0.6 U/µl restriction enzymes (pSXG: BamHI/EcoRI, 
pQE30:BamHI/HindIII) and 40 ng/µl plasmid DNA. The reaction was carried out at 37 °C 
for 3 hours. The digested plasmids were purified from a 1% agarose gel using a 
Nucleospin® Gel and PCR clean-up column. Concentrations of digested DNA inserts and 
plasmid vectors were determined using absorbance measurement at 260nm with 
NanoDrop.  
 
The digested bromodomain DNA segments were inserted into the plasmid vectors pSXG 
and pQE30 by ligation with T4 ligase. Digestion with BamHI and EcoRI/HindIII left 
overhanging “sticky” bases on the inserts and vectors. The inserts were ligated into the 
vectors with a 1:3 vector to insert ratio. The amount of insert to be used for each reaction 
was determined using equation 3.1: 
 
𝑚𝑎𝑠𝑠 𝑣𝑒𝑐𝑡𝑜𝑟 (𝑛𝑔)𝑥 𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 (𝑘𝑏)
𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 (𝑘𝑏)
 𝑥 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 
𝑖𝑛𝑠𝑒𝑟𝑡
𝑣𝑒𝑐𝑡𝑜𝑟
= 𝑚𝑎𝑠𝑠 𝑖𝑛𝑠𝑒𝑟𝑡 (𝑛𝑔) 
 
An amount of 100 ng vector was used in the ligation reactions. Ligations were carried out 
in a 20 µl reaction volume in 1X ligation buffer with 400 units T4 DNA ligase for 17 hours 
at 16 °C. The enzymes in the reaction were inactivated by heating to 65 °C for 10 minutes. 
An aliquot of 5 µl of the ligation reaction was used for heat-shock transformation with 50 
µl chemically competent E.coli XL1-blue cells. Transformed cells were plated on LB agar 
plates with ampicillin for selection and growth. To check for successful ligation, colony 
PCR was performed in a 10 µl reaction with 1X GoTaq Flexi buffer, 2.5 mM MgCl2, 0.8 µM 
forward and reverse sequencing primers (table 2.12), 0.2 mM dNTPs and 0,1 U/µl 
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Table 3.2: Thermocycler program for colony- PCR 
Step Temperature Time Cycles 
Initial denaturation 94 °C 5 minutes  1 
Denaturation 95 °C 30 seconds  
Annealing Tm 30 seconds 25 
Elongation 72 °C 1 minute  
Final elongation 72 °C 5 minutes 1 
 
3.1.5 Bromodmomain plasmid construct amplification and sequencing 
Colonies that were expressing the ampicillin resistance gene were picked and grown in 5 
ml LB mini-cultures with 100 µg/ml ampicillin for plasmid amplification, followed by 
mini-prep purification with NucleoSpin® Plasmid mini-prep kit. Plasmid constructs were 
sequenced in a 10 µl reaction containing, 150 to 300 ng of purified plasmid, 1 µl BigDye 
v.3.1, 1 µl sequencing buffer and 3,2 pmol of each primer. Cycle sequencing was carried 
out in a thermocycler with the program shown in table 3.3. After amplification, an 
additional 10 µl dH2O was added to the reaction, and the samples were subjected to DNA 
sequencing at the in-house sequencing facility in a 3530xl DNA Analyzer from Applied 
Biosystems.  
 
Table 3.3: Thermocycler program for DNA sequencing  
Step Temperature Time Cycles 
Initial denaturation 96 °C 5 minutes  1 
Denaturation 96 °C 10 seconds  
Annealing 55 °C 5 seconds 25 
Elongation 60 °C 4 minutes  
 
Table 3.4 shows the name and description of bromodomain constructs that were made 
and verified by sequencing.  
 




Table 3.4: Brd4 bromodomain constructs verified by DNA sequencing 
Construct Description* Tag 
pSXG-BD1 First bromodomain (BD1) of Brd4 in 
pSXG vector 
N-terminal GST 
pSXG-BD2 Second bromodomain (BD2) of Brd4 in 
pSXG vector 
N-terminal GST 
pSXG-BD1+BD2 First and second bromodomains of Brd4 
in pSXG vector 
 
N-terminal GST 
pQE30-BD1 First bromodomain of Brd4 in pQE30 
vector 
N-terminal 6x His-tag 
pQE30-BD2 Second bromodomain of Brd4 in pQE30 
vector 
N-terminal 6x His-tag 
pQE30-BD1+BD2 First and second bromodomains of Brd4 
in pQE30 vector 
N-terminal 6x His-tag 
*See figure 4.1 for details on bromodomain residues included in the constructs 
 
3.2 Protein Expression and Purification 
3.2.1 Expression of recombinant bromodomains 
pSXG constructs (shown in table 3.4) were transformed by heat shock into chemically 
competent E.coli BL21-CodonPlus-RIL cells, while pQE30 constructs were transformed 
into E.coli M15 cells. Transformed bacteria were plated on LB-agar plates with ampicillin, 
and grown over night at 37 °C. Single colonies of transformed cells were picked and grown 
in 5ml LB mini- culture overnight at 37 °C with 100 µg/ml ampicillin. Start-up cultures 
were diluted in 750 ml fresh LB medium to an OD600 of 0.1. Expression of Brd4 
bromodomain fusion proteins was accomplished by growth at 37 °C to an OD600 of 0.5, 
and then further growth at 18 °C until OD600 0.8 was reached. Protein expression was 
induced by the addition of IPTG to a final concentration of 0.1 mM. Bacteria were 
harvested after roughly 16 hours by centrifugation at 8,700 x g for 15 min at 4 °C. 
Expression of GST and GST-p300B was induced by the addition of 0.4 mM IPTG after an 
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OD600 of 0.8 had been reached by growth at 37˚C. Cells were harvested after 2 hours by 
centrifugation at 8,700 x g for 15 min at 4 °C. 
Expression was verified using SDS-PAGE, as described in section 3.4.1. The theoretical 
parameters for expressed proteins are given in table 3.5. 
 







coefficient [M-1 cm-1] 
Theoretical 
pI 
GST-BD1 42.6 69,790 6.68 
GST-BD2 42.5 57,300 6.43 
GST-BD1+BD2 74.7 84,230 8.74 
GST 25.7 43,110 5.90 
GST-p300B 41.3 70,040 6.36 
His-BD1 16.3 27,055 8.49 
His-BD2 16.0 14,440 7.17 
His-BD1+BD2 48.3 41,370 9.16 
*Calculated with ProtParam online resource  
 
3.2.2 Purification of GST-fusion proteins 
GST-fusion proteins were affinity-purified using glutathione Sepharose affinity 
purification resin. Bacterial pellets were washed in 40 ml PBS, and resuspended in 10 ml 
GST- purification lysis buffer per 1 g pellet wet-weight. Cells were lysed by sonication for 
15 seconds at 60% intensity, with 30 seconds pauses, for a total sonication time of 2 
minutes on ice. After sonication, 500 µl 20% Triton x-100 was added per 10 ml cell lysate, 
and incubated for 30 min at 4 °C. The cell lysate was centrifuged at 12 096 g for 6 minutes. 
The cleared supernatant was collected and 500 µl 50% glutathione Sepharose slurry was 
added. The cleared lysate was allowed to mix with the slurry on a soft shaker at 4 °C for 
30 min. The slurry was collected by centrifugation at 2850 g for 6 min and washed twice 
with 5 ml cold GST-purification lysis buffer. Proteins were eluted by the addition of 400 
µl glutathione elution buffer and incubation at 4 °C for 45 min. Eluates were collected by 
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1 minute centrifugation at 13,000 rpm in a tabletop minifuge. Eluted proteins were 
dialyzed GST-purification lysis buffer without protease inhibitor, overnight at 4 °C in 
Slide-A-Lyzer cassettes with 10.000 MW cutoff. The concentration of purified proteins 
was determined by absorbance measurements at 280 nm with NanoDrop. The online 
resource ProtParam was used to estimate the theoretical molecular weights and 
extinction coefficients of the GST- fusion bromodomains (Table 3.5).  Protein purity was 
examined with SDS-PAGE, as described in section 3.4.1.  
 
3.2.3 Purification of his-tagged proteins  
His-tagged proteins were purified by immobilized metal affinity chromatography, using a 
Ni-NTA agarose column. Bacterial pellets were thawed on ice and resuspended in 10 ml 
IMAC lysis buffer per 1 g pellet. The bacterial suspension was incubated with 1 mg/ml 
lysozyme on ice for 20 minutes. Cells were lysed by sonication at 60 % intensity for 15 
seconds with 30 second pauses to a total of 2 minutes. The lysate was centrifuged at 
16,000 g for 20 minutes. The column was equilibrated by three column volumes of IMAC 
wash buffer. The cleared lysate was filtered through a 0.45 µm filter and allowed to flow 
through the column twice by gravity flow. A total of 5-15 column volumes (CV) of IMAC 
wash buffer was then added, before the protein was eluted with 2 CV of IMAC elution 
buffer. Protein concentration was measured with NanoDrop, while the purity was 
examined with SDS-PAGE as described in section 3.4.1.  
 
3.3 Determining degree of protein aggregation 
3.3.1 Size exclusion chromatography 
Principle 
Size exclusion chromatography (SEC) can be used to estimate the molecular weight of 
proteins. Separations of proteins by SEC is based on the Stokes radii. If a calibration curve 
of known proteins is constructed, the method can be used to estimate the molecular 
weight of an unknown protein. The standard curve is made by plotting the partition 
coefficients (Kav) of a series of standard proteins against the logarithm of their molecular 
weight. The partition coefficient describes the degree of interaction between a given size 
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exclusion media and an analyte for a given set of experimental parameters (Hong et al., 
2012).The Kav is calculated using equation 3.2, where Ve is the elution volume for the 
protein, V0 the column void volume and Vc the geometric column volume. The void volume 
is equal to the elution volume for the standard molecule Blue Dextran 2000, which is a 
large polymer of anhydroglucose with an approximate molecular weight of 2000 kDa. 
Because of its size, this polymer will be eluted prior to most other complexes and proteins. 







To determine the oligomeric state of purified His-tagged BD1, SEC was performed. His-
BD1 was purified as described above, and 0.5 ml of 4 mg/ml (245 µM) was loaded on a 
120 ml Superdex 75 prepgrade 16/600 column connected to an ÄKTA explorer FPLC 
system. The flowrate was set to 1 ml/min and elution was monitored by measuring 
absorbance at 280 nm. A standard curve was made from elution data of standard proteins 
which are presented in table 3.6. The standard proteins were analyzed under the same 
conditions as His-BD1. In order to determine the oligomeric status of His-BD1 The 
equation from the linear regression was used to calculate the molecular weight of his-
BD1.  
 
Table 3.6: SEC standard proteins 
Protein Molecular weight (kDa) 
Albumin 66 
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3.3.2 Dynamic light scattering 
Principle 
Dynamic light scattering (DLS) is a method for measuring the hydrodynamic size and size 
distribution of molecules and particles in solution or suspension. Laser light is directed 
into the sample, and the Brownian motion of particles in suspension causes the light to be 
scattered at different intensities. Analysis of these fluctuations yields the velocity of the 
Brownian motion, which is directly related to the particle’s hydrodynamic radii (Wyatt 
Technology, 2015). The reported particle size parameter from a DLS experiment is the 
hydrodynamic diameter, defined as “the size of a hypothetical hard sphere that diffuses 
in the same fashion as that of the particle being measured” (Malvern Instruments 2011). 
The degree and rate of aggregation can be measured by DLS, by investigating whether the 
hydrodynamic diameter of the particle increases over time. 
Execution 
Particle sizes and degree of aggregation of the His-tagged Brd4 bromodomains were 
determined using DLS. After purification of His-BD1 and His-BD2, the buffer was 
exchanged to a 50 mM Tris-HCl, 150 mM NaCl, 1 mM DTT buffer at pH 7.5 using a PD-10 
desalting column. Dynamic light scattering was measured at a protein concentration of 
214 µM for His-BD1, and 131 µM for His-BD2. Before the measurement was conducted a 
standard operating procedure (SOP) was set up for size determination, and in the SOP the 
dispersant viscosity was set to reflect the buffer in use. Measurements were done in a 
Zen2112 quartz cuvette at 25 °C. The His-BD1 sample was centrifuged at 20 000 g for 10 
min before measurements to remove insoluble material. Measurement of 280 µM 
lysozyme (14.3 kDa), a monomeric protein with similar molecular weight as His-BD1 and 
His-BD2, under the same conditions was used as a control. The rate of aggregation of His-
BD1 was measured by reading the dynamic light scattering at 5 min intervals over a time 
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3.4 Histone peptide binding assay 
Principle 
In the histone peptide binding assay (Shi et al., 2006), the protein of interest is mixed with 
a short synthetic biotinylated peptide with desired modifications. A streptavidin- 
Sepharose resin is then added, and the biotinylated peptide will bind to it. If the protein 
of interest interacts with the peptide, it too will be retained on the Sepharose resin. After 
several steps of washing, the protein-peptide complexes are eluted from the resin, and the 
composition of the eluate is investigated by immunoblotting. 
Execution 
 Several acetylated and unmodified histone peptides were used in the binding assay, and 
are listed table 2.14. Purified GST-fusion proteins were mixed with biotinylated histone 
peptides at a 0.1:1 µM ratio in 150 µl Shi buffer. This mix was incubated on a rotating 
wheel overnight at 4 °C. Aliquots of 15 µl streptavidin Sepharose slurry were added, and 
the samples were incubated at 4 ° for one hour on a rotating wheel. The samples were 
centrifuged at 1500 g for 2 min, and resin was washed four times with 200 µl Shi buffer, 
and two times with 200 µl 50 mM Tris-HCl pH 8.0. After washing, the resin was 
resuspended in 30 µl 2x SDS sample buffer and heated at 95 °C for 5 minutes. Aliquots of 
10 µl of resuspended resin were analyzed by immunoblotting with anti-GST antibody.  
3.4.1 SDS-PAGE 
SDS-PAGE was carried out to separate proteins by molecular weight and for analysis with 
immunoblotting. The electrophoresis of GST-fusion domains was carried out in 12% 
polyacrylamide-SDS gels at 25 mA in 1x TGS buffer, while 15% gels were used for the 
smaller, his-tagged domains. 
3.4.2 Immunoblotting 
Immnunoblotting was used to detect proteins that had bound to biotinylated peptides in 
the histone peptide binding assay, and been separated with SDS-PAGE. The 
immunoblotting was carried out using polyvinylidene fluoride blotting membrane 
(PVDF). The blotting membrane was activated by treatment with 100% methanol for 5 
seconds, followed by a 5 minutes wash with dH2O. Membrane, polyacrylamide gel and 
blotting paper were equilibrated in cold transfer buffer for 10 min before blotting. 
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Transfer was performed in a Trans-Blot Turbo semi-dry transfer system for 20 min, 25 V, 
1mA. After the transfer, the membrane was blocked with 5% skimmed milk in 1x PBS, 
0.05% tween for 1 hour. After blocking, the membrane was incubated with polyclonal 
anti-GST antibody, at a 1:10,000 dilution in 5% skimmed milk PBS, 0.05% tween 
overnight at 4 °. The membrane was washed with PBS, 0.05% tween 4-6 times in 60 min 
(6 x 10 min) at room temperature before incubation with HRP-conjugated secondary 
antibody at 1:10,000 dilution for 1 hour in 5% skimmed milk, PBS, 0.05% tween. 
Secondary antibody was washed off with six washes with PBS, 0.05% tween. GST-
antibody complexes were detected by 5 minutes incubation with ECL Prime western 
blotting reagent. Imaging of the membrane was conducted in a ChemiDoc XRS+ imaging 
system using ImageLab v.3.0.  
 
3.5 Isothermal titration calorimetry 
Principle 
Isothermal titration calorimetry (ITC) is a method that can measure binding reaction 
parameters such as the strength of association, the stoichiometry and the 
thermodynamics of a reaction. It measures the heat that is released or consumed by 
stepwise titration of a ligand into a solution of the macromolecule/protein of interest. The 
strength of a binding reaction is usually expressed in the form of Ka, the association 
constant, or as the Gibbs free energy.  In protein-ligand binding reactions, the dissociation 
constant, Kd, which is the inverse of Ka, is used to describe the affinity between a ligand 
and a protein. The stoichiometry of the binding reaction is represented by the symbol n, 
which gives the number of available binding sites per protein. The enthalpic and entropic 
contributions to the overall free energy of the binding reaction can also be determined in 
an ITC experiment.  
The ITC instrument consists of two cells, one reference cell that contains water or a 
reference liquid, and one sample cell that contains one of the reactants, often the protein 
or macromolecule. These two cells are kept at a constant temperature in the system. The 
other reactant, is added to the sample cell through an automated syringe in small stepwise 
injections. Addition of ligand into the protein solution causes either release or 
consumption of energy, and this will either heat or cool the solution compared to the 
   3. Methods 
38 
 
reference cell. The ITC instrument will register the heat difference between the reference 
cell and the sample cell, and compensates by keeping the two cells at the same 
temperature (Wilson & Walker, 2010). The amount of power over time that is spent 
before the sample cell reaches its steady-state temperature after an injection of ligand is 
measured and is the experimentally determined quantity. This, so called corrected heat 
rate, is directly proportional to the heat of the reaction in the sample cell (Freire et al., 
1990), and is given by equation 3.3 
𝑞 = 𝑉∆𝐻∆[𝐿𝑏] 
 
Where q is the heat, V is the reaction volume, ΔH is the enthalpy of binding and Δ[Lb] is 
the change in bound ligand concentration.  
The concentration of ligand in the syringe is often several fold higher than that of the 
protein in the sample cell, and after some injections, the proteins’ binding sites become 
saturated. This effect can be observed from the recorded raw data as the peaks of applied 
power decreases because of the smaller change in heat for the reaction. Subsequent 
injections produce small peaks that correspond to dilution or mechanical effects which 
must be subtracted from the injection peaks before analysis (Leavitt and Freire, 2001). 
The raw data is fitted to a binding model which estimates the variable model parameters 
through equation 3.3. Analysis of the data yields the enthalpy (∆𝐻) and the association 
constant, Ka, of the interaction. These two parameters can further be used to calculate the 
Gibbs free energy (∆𝐺) and the entropy(∆𝑆) of the interaction. The most widely used 
model for the analysis of binding data is the Multiple Sets of Independent Binding Sites 
model, which assumes that all possible binding sites in the protein have the same affinity 
for the ligand. This model can be used for simple 1:1 binding. (Freire et al., 1990). 
Execution 
His- tagged Brd4 bromodomains were purified as described above (Section 3.2.3), and 
dialyzed to appropriate buffers. His-BD1 was dialyzed in Slide-A-Lyzer MINI units (MWCO 
3,500) for 1h at 4 °C, to T7.5 buffer. His-BD2 was dialyzed overnight in Slide-A-lyzer 
cassettes (MWCO 3,500) to buffer T8.5. The difference in buffers was due to the different 
isoelectric points of the two domains (Table 3.5). After dialysis, the proteins were diluted 
to a concentration of approximately 40 µM in T7.5 or T8.5 buffer. Histone peptides were 
Equation 3.3 
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prepared by weighing out the appropriate amount of lyophilized peptide, and dissolving 
it in either T7.5 or T8 .5 buffer to a concentration of approximately 1 mM. Peptide and 
protein concentrations were accurately measured by spectrophotometry NanoDrop, 
using extinction coefficients calculated with ProtParam (Table 2.13). Binding assays were 
performed at 25 °C with 20 continuous titrations of 2.03 µl 700- 1000 µM peptide into 
300 µl 40 µM protein, with a constant stir rate of 300 rpm.  Peptide titrated into buffer 
was used as a control/blank experiment, and was subtracted from collected data before 






















Acetylation of lysine 27 in histone H3 (H3K27ac) is a histone modification found in active 
enhancers, but not in primed or poised enhancers. Recognition of this mark by a specific 
reader protein might be important for enhancer activity and subsequent transcriptional 
activation at promoters. Brd4 was chosen as a candidate protein for specific recognition 
of H3K27ac due to its reported co-localization with this mark across the genome (Lovén 
et al., 2013), and previous large-scale bromodomain binding arrays which suggested 
interactions between the two (Filippakopoulos et al. 2012). To determine if Brd4 binds 
H3K27ac in vitro, and to characterize specificity and affinity of this interaction, binding 
assays with histone peptide binding pulldowns, isothermal titration calorimetry (ITC) and 
surface plasmon resonance (SPR) were performed. With these three methods, the 
interactions between bromodomains of Brd4 and synthetic histone tail peptides were 
studied. While histone peptide binding assays can give qualitative information on binding 
specificity, ITC and SPR can give quantitative information about the interactions, based 
on thermodynamics and kinetics respectively. Only the results from histone peptide 
binding assays and ITC are presented here, as technical difficulties rendered the SPR data 
unsuitable for interpretation.  
4.1 Construction of human Brd4 bromodomain expression vectors 
Both bromodomains of human Brd4 were to be tested for binding to H3K27ac, and thus 
different domain constructs containing either one or both bromodomains were created. 
Primers for two different sets of Brd4 constructs were created, one set which included 
only the core bromodomain sequences with five flanking residues on either side (BD1-s 
and BD2-s), and one set where BET-family-specific flanking sequences were included 
(BD2 and BD2) (Figure 4.1 and 4.2). A construct containing both Brd4 bromodomains, 
BD1 and BD2, was also created (Figure 4.2), however, this construct was not used in 
further experiments as it exhibited severe degradation after purification. In addision, 
primers for the creation of a full-length Brd4 construct were also prepared, but PCR 
amplification of this sequence was unsuccessful. Human Brd4 bromodomain sequences 
were retrieved from UniProtKB (BRD4_HUMAN). As can be seen from the multiple 
sequence alignment in figure 4.1, Brd4 bromodomain sequences retrieved from UniProt 
(BD1-s and BD2-s) did not include all secondary structure elements. Brd4 constructs were 
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created by PCR of cDNA from HeLa cells, and subsequent cloning into pSXG (for 
expression of GST-fusion proteins) and pQE30 (for expression of His-tagged proteins) 
expression vectors. Pilot protein expressions of the Brd4 constructs showed higher 
protein expression levels from constructs that contained BET-specific flanking amino 
acids, and consequently these constructs were used for the expression of Brd4 





Figure 4.2: Brd4 bromodomain constructs. Brd4-FL: Construct containing the entire Brd4 sequence. 
BD1, BD2 and BD2+BD2: Brd4 bromodomain constructs containing BET-family specific flanking 
sequences. BD1-s and BD2-s: Shorter Brd4 bromodomain constructs containing only the core 
bromodomain sequence, as found in UniProtKB.  
Figure 4.1: Multiple sequence alignments of BD1 and BD2 of the human BET-family: BD1 and BD2 
marked by black lines, indicate Brd4 BD1 and BD2 bromodomains with BET-family specific flanking 
sequences. BD1-s and BD2-s: shorter constructs that were made from BD1 and BD2 sequences retrieved 
from UniProtKB. BD1 and BD2 secondary structure are indicated with red lines, and was found from 
BD1 (2OSS) and BD2 (2OUO) crystal structures in PDB.  Multiple sequence alignments were created 
with Clustal Omega. 
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4.2 Expression and purification of GST-bromodomain fusion proteins 
GST- Brd4 bromodomain proteins, expressed from the pSXG vector, were used in histone 
peptide binding assays. In addition to enhancing protein stability and solubility (Nygren 
et al., 1994), the GST-tag enabled immunoblotting of fusion proteins, as there are no 
available antibodies for specific recognition of the Brd4 bromodomains. GST-
bromodomain fusion proteins were bacterially expressed in E.coli BL21-RIL at 18˚C over-
night, (Section 3.21). The GST-fusion bromodomain from human acetyl-transferase p300 
(HUMAN_EP300), denoted p300B, and GST alone were also expressed to serve as positive 
and negative controls in the following experiments.  
GST-fusion bromodomains were found to be soluble and exhibited low levels of 
degradation after expression, indicated by the presence of a polypeptide migrating as 25 
kDa, corresponding to the GST part of the fusion proteins (Figure 4.3). The bacterially 
expressed proteins were purified by GST-affinity chromatography (Section 3.2.2). As the 
vast majority of proteins in the eluate fraction had the expected molecular sizes (Figure 







Figure 4.3: Expression of GST-fusion Brd4 bromodomains BD1 and BD2, and control proteins. 
Protein expression was induced with 0.1 mM IPTG at 18˚C over-night, and verified by SDS-PAGE analysis 
followed by Coomassie staining. 10 µl whole cell lysate was loaded.  Bands of interest are indicated with 
yellow asterisks, and have the following expected molecular weights: GST-BD1; 42.3 kDa, GST- BD2; 42 
kDa, GST; 25.7 kDa and GST-p300B; 41.3 kDa.  







4.3 Histone peptide binding assays show no interaction between Brd4 
bromodomains and H3K27ac 
The first binding study performed to test the potential binding between Brd4 
bromodomains and H3K27ac was a histone peptide binding assay. The assay was 
performed with GST-fused Brd4 bromodomains and a panel of synthetic biotinylated 
histone peptides. The biotin moiety on the peptides allowed the separation of GST-fusion 
proteins bound to histone peptides from unbound protein, through the precipitation of 
peptide-protein complexes with streptavidin-coated Sepharose beads. The GST moiety 
served as an epitope tag in the subsequent analysis of the complexes by SDS-PAGE 
immunoblotting. Non-modified (H3 and H4) and methylated (H3K27me1) histone 
peptides were included as negative controls, while a H4 peptide acetylated at K5, K8, K12 
and K16 (H4tetra-ac) was included in the experiments as a positive control for 
bromodomain binding.  Many bromodomains, including BD1 and BD2 of Brd4, have been 
reported to have higher affinities for peptides that have two acetyl-lysines separated by 
1-5 amino acids (Morinière et al., 2009). An H3 histone peptide acetylated at both K27 
and K23 (H3K23,K27ac) was therefore included in the assay to determine if the additional 
acetyl-lysine would be a better ligand for BD1 and BD2.  The bromodomain of 
acetyltransferase p300 is known to bind H4tetra-ac histone peptides (Rack et al., 2014) 
and was therefore used as a positive control in the peptide pulldown assay, while GST 
Figure 4.4: Purification of Brd4 bromodomains by GST-affinity chromatography. 5 µl of each 
fraction was analyzed by SDS-PAGE followed by Coomassie staining. Purified proteins of interest are 
marked by yellow asterisks. (A): GST-BD1 (42.3 kDa) and GST-BD2 (42 kDa). (B): p300B (41.3 kDa) and 
GST (25.7 kDa). L: whole bacterial lysate, FT: resin flow-through, E: eluate 
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alone was included as a negative control. To check the possibility of unspecific binding of 
the proteins to the streptavidin- conjugated beads, an experiment without histone 
peptides was also performed.  Different peptide to protein molar ratios were tested for 
histone peptide binding assays, and a ratio of 10:1 (1:0.1 µM) peptide to protein was found 
to be most suitable as it gave the lowest level of unspecific binding.  
 
Four replicates of peptide binding assays were performed with each fusion protein. In all 
experiments GST showed a low level of binding to all biotinylated peptides, whereas GST-
p300B and GST-BD1 showed strong binding to H4tetra-ac peptide (Figure 4.5). GST-BD2 
binding to H4tetra-ac peptide was detected in only one experiment (Figure 4.4.B). A low 
level of unspecific binding to the beads was detected, especially in the case of GST-BD1 
(Figure 4.4.A). The rather strong signal was present only in one out of three replicates that 
included a “beads only” control. Compared to background signals, no binding of the fusion 







Figure 4.5: Histone peptide binding assays show no specific binding between Brd4 
bromodomains and H3K27ac peptide. Biotinylated histone peptides and recombinant GST-BD1, GST-
BD2, GST-p300B and GST were used as indicated. 10% of input and 33% of eluate fractions were 
analyzed after SDS-PAGE by immunoblots using anti- GST antibody. Abbreviations: H3/H4, non-
modified histone peptides (residues 1-21 aa and 2-24 aa, respectively.) H4tetra-ac: H4 peptide 
acetylated at K5,8,12, and16. Two replicates of four experiments are presented in A and B. 
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4.4 Expression and purification of His-tagged Brd4 bromodomain 
proteins 
As our peptide binding assays gave conflicting results compared to previously published 
studies (Filippakopoulos et al., 2012), ITC was employed for determining whether Brd4 
bromodomains bind to the H3K27ac peptide. As the presence of the GST-moiety could 
disturb measurements in ITC, His-tagged Brd4 bromodomain constructs were created. 
The same Brd4 bromodomain sequences as for GST-constructs were used for the His-
tagged constructs (Figure 4.1). Protein expression was carried out in E.coli M15 cells over-
night at 18 ˚C, and analyzed with SDS-PAGE and subsequent Coomassie staining (Figure 
4.6). Samples from induced bacterial cultures showed high level of expression of all Brd4 
bromodomain constructs. 
Expressed His-tagged Brd4 bromodomain proteins were purified using immobilized 
metal affinity chromatography (IMAC) (Figure 4.7). His-BD1+BD2 protein exhibited a 
severe degradation pattern after purification (data not shown), hence this construct was 
not used in following experiments. His-BD2 had a high purity, as bands not corresponding 
to the expected protein size were very weak after Coomassie staining. A more intense 
band of lower molecular weight was visible in the eluate lane of His-BD1. A band of this 
size can be seen in the lysate of both His-BD1 and His-BD2, but it is only retained in the 
eluate of His-BD1 (Figure 4.7). Using Bio-Rad’s Image Lab software to determine the 
relative intensity of the bands, purified His-BD1 gave an estimated purity of 85-90%. His-
BD1 was, however, not stable in solution, and started to precipitate 3 hours after 
purifications. Precipitation of His-BD2 was observed two days after purification, when 
stored at 4˚C. 









4.5 Analysis of His-tagged bromodomain aggregation by SEC and DLS  
As His-BD1 showed signs of precipitation after purification, measurements of particle 
sizes and degree of aggregation were performed by size exclusion chromatography (SEC) 
and dynamic light scattering (DLS). His-BD1 precipitated in several tested buffers, 
including Tris and HEPES buffers at pH 6.7, 7.5, 8.5 and 9. There was a slight decrease in 
the extent of precipitation of His-BD1 in buffers with 50 mM Tris and 300 mM NaCl 
compared to buffers with 50 mM Tris and 150 mM NaCl. After overnight storage at 4˚C 
Figure 4.7: IMAC purification of His-
tagged Brd4 bromodomains. His-
tagged proteins were purified on a Ni-
NTA agarose IMAC column. 5 µl of each 
fraction was analyzed by SDS-PAGE 
followed by Coomassie staining. 
Purified proteins of interest are 
marked by yellow asterisks: His-BD1 
(16.3 kDa), His-BD2 (16.0 kDa). L: 
whole bacterial lysate, FT: column 
flow-through, W: column wash E: 
eluate. 
 
Figure 4.6: Expression of His-tagged 
Brd4 bromodomains BD1 and BD2. 
Protein expression was induced with 0.1 
mM IPTG at 18˚C over-night, and verified 
by SDS-PAGE analysis followed by 
Coomassie staining. 10 µl of whole cell 
lysate was loaded. Bands of interest are 
indicated with yellow asterisks, and have 
the following expected molecular 
weights: His-BD1:16.3 kDa, His- BD2: 16 
kDa. His-B1+BD2: 48.3 kDa. 
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there were however visible signs of precipitation even in buffers with higher salt 
concentration. 
4.5.1 His-BD1 aggregates in solution 
SEC was performed to investigate if purified His-BD1 was present as a monomer, or in 
higher oligomeric states. The molecular weight of species present in the His-BD1 elution 
profile were estimated from a standard curve made from a selection of calibration 
proteins of known molecular weight. The calibration proteins were separated by SEC in 
the same manner as His-BD1 (Figure 4.8.B), and a standard curve was made by plotting 
the partition coefficient, Kav, calculated from their elution points (Equation 3.2), as a 
function of the logarithm of their molecular weights. Linear regression of this plot yielded 
equation 4.1, which was subsequently used to calculate the molecular weights of proteins 
in the His-BD1 sample. The calculated values are however indicative, as there is no perfect 
correlation between stokes radius and molecular weight, as the proteins can have 
different shapes 
The elution profile of His-BD1 displayed three distinct peaks (b, c and d) indicating that 
the sample contained particles of three different sizes (Figure 4.8.A). An additional signal 
not present in the calibration standards was detected in the void volume of His-BD1 (a). 
The molecular weight of particles eluted in the void volume cannot be determined from a 
calibration standard curve, as their sizes are too large. Only two different proteins can be 
identified from SDS-PAGE of His-BD1 prior to SEC (Figure 4.7), one intense band 
corresponding to His-BD1, and a weaker, smaller band that might be an impurity or a 
degradation product.   













A molecular weight of 13 kDa was calculated for peak c in His-BD1. The theoretical 
molecular weight of His-BD1 is 16.3 kDa, and therefore this peak was assumed to 
correlate with monomeric His-BD1.  Since the area under peak a, which was eluted in the 
void volume, could not be determined, it was not possible to calculate the fraction of 
monomeric His-BD1 in the sample. Peaks b and d, the two smaller peaks observed in the 
Figure 4.8: SEC elution profile of his-BD1 and standard proteins. Separation by SEC was performed 
in a 120 ml Superdex 16/600 column, at flow rate 1 ml/min. A: Elution profile of His-BD1. A 0.5 ml 
sample of 245 µM His-BD1 was loaded on the column. B: Elution profile of a series of standard proteins; 
Albumin (66 kDa), Carbonic anhydrase (29 kDa), Lysozyme (14.3 kDa) and Aprotinin (6.5 kDa). Blue 
dextran (~2,000 kDa) was included to estimate the void volume Vo. C: SEC calibration curve of the 
partition coefficient Kav of selected protein standards as a function of their log molecular weight (kDa). 
Peaks from SEC of His-BD1 (A) are shown as triangles. R2 of regression was 0.95. 
Equation 4.1 
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elution profile, were estimated to be 53 and 5 kDa, respectively. No polypeptide migrating 
as 53 kDa is visible in SDS-PAAG of His-BD1, which suggests that the presence of this peak 
in the SEC data is due to aggregation of His-BD1 into a larger complex. The molecular 
weight of the species eluted in the void volume (peak a) could not be determined, but its 
presence also suggests that His-BD1 forms large aggregates in solution. 
 
4.5.2 DLS of His-BD1 revealed extensive aggregation  
As SEC experiments suggested that His-BD1 aggregated in solution, dynamic light 
scattering (DLS) was performed to investigate the particle size distribution of His-BD1. 
The hydrodynamic particle sizes of His-BD1 were measured after 20 minutes 
centrifugation to remove insoluble particles.  The monomeric protein lysozyme (14.3 
kDa) was included as a control, as it has similar molecular weight as His-BD1 (16.3 kDa). 
Three independent particle-size readings were made for each protein. The particle size 
measured by DLS is called hydrodynamic diameter, and gives the diameter of a hard 
sphere that migrates like the measured particle in solution. However, in practice, particles 
and macromolecules in solution are non-spherical and surrounded by a hydration shell. 
Because of this, the reported particle diameter will give an indication of the apparent size 
of the dynamic solvated particle. The hydrodynamic particle sizes determined by these 
DLS experiments are not considered to give the absolute size of the molecules, but to give 
indications of the oligomeric state of the proteins in question. The DLS data presented 
here are the first order results from the experiments, where an intensity distribution of 
particle sizes is shown. The particle scattering intensity is proportional to the square of 
the molecular weight, and therefore this distribution is a sensitive detector for the 
presence of large particles and aggregation. This means that more weight is given to larger 
particles in the intensity distribution, and that the reported intensity peaks are not 
proportional to the number of particles with each diameter. 
 
 For His-BD1, five peaks were observed from the DLS data (Figure 4.9.A). Peaks 3 and 5 
were only found in the first and third reading, while 2 and 4 were only observed in the 
second reading. The peak with the highest intensity present in His-BD1 had a mean 
hydrodynamic diameter of 6.2 nm, and a peak diameter of 5.6 nm. The particle size 
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measurement of lysozyme revealed only one peak, as expected (Figure 4.9.B). The 









Table 4.1: Particle size distribution of His-BD1 and lysozyme 
Peak Mean particle 
diameter* (nm) 




1 6.41, 5.82, 6.23 11.7, 13.0, 13.2 83.0, 73.5, 82.7 52.3, 40.5, 48.1 
2 84.82 1.2 7.5 41,180  
3 1921, 1753 1.7, 1.6 13.5, 13.6 350,655; 275,786 
4 10542 1.3 12.9 Too large 
5 42851, 37563 0.8, 0.6 3.5, 3.6 Too large 
Lysozyme 5 19.1 100 27.5 
*Two times stokes radius 
1,2,3 Readings 1,2 and 3 
+ 𝑟 = 0.483(𝑀𝑤)0.386 – r: Stokes radius (Å), Mw: Molecular weight (kDa) (Venturoli and Rippe, 2005) 
 
Figure 4.9: The His-BD1 sample is polydisperse: Particle sizes were measured by DLS. A: Three 
independent readings of the particle size distribution of a His-BD1 sample (214 µM). Three separate 
readings are shown in different colors. B: Three independent DLS readings of the particle size 
distribution of lysozyme (300 µM).  
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SDS-PAGE of His-BD1 showed two proteins present after purification, one corresponding 
to the expected size of His-BD1, and a smaller, less abundant protein. However, there is 
no indication of the presence of a smaller particle with low intensity in the DLS results. 
Peaks 2,3,4, and 5 indicate the presence of large aggregates in the sample. The width of 
the particle size distribution is reported as dimensionless parameters known as the 
polydispersity index (Pdi). This value describes the degree polydispersity in a sample. 
Values smaller than 0.05 are rare, and most often seen only in highly monodisperse 
standards, while a Pdi greater than 0.7 indicates a very broad size distribution which is 
not suitable for DLS (Malvern Instruments 2011). Samples with a Pdi below 0.1 are 
usually considered monodisperse. The Pdi of His-BD1 was reported as 0.3, while that of 
lysosome was found to be 0.06. These data indicate that His-BD1 aggregates in solution, 
and causes the formation particles of larger and varied sizes.  
 
4.5.3 His-BD1 exhibits rapid aggregation  
To determine the rate and extent of the aggregation, an experiment was performed where 
the particle sizes of His-BD1 were recorded every 5 minutes for a time period of 
approximately 16 hours. The collected data points were examined and the intensity of 
peaks that formed or declined over the time course were plotted (Figure 4.10). Only 
particles that showed a stable presence in the sample were plotted, and peaks that rapidly 
formed and declined are not shown. The plotted particles were followed by their peak 
diameter, and not the mean diameter calculated from the width of their curves. Three 
peaks were found to stably inhabit the His-BD1 sample, corresponding to peaks 1,3 and 4 
from figure 4.9.A. The plot of His-BD1 particle distribution over time showed a decrease 
in intensity of peak 1, assumed to be the monomeric form of His-BD1, over time. After only 
56 minutes, the intensity of peak 1 was halved. The intensity of peak 3, however, increased 
by 4 times in the same time period.  






After 300 minutes, the sample was dominated by peak 4, a large particle with a diameter 
of 1484 nm. The intensity of peak 1 never reached zero, but stayed at a constant level of 
2-3% after the first 100 minutes. After the 300 minutes shown in figure 4.10.A, the data 
became uneven and large spikes in intensities were observed. The spikes in intensity 
obscured the data, and therefore only the first 300 minutes of the time-scale are 
presented.   The particle size distribution of His-BD1 after 300 minutes was drastically 
different from that seen at the start of the experiment (Figure 4.10.B). As large particles 
obscure the presence of smaller ones, the fraction of monomeric His-BD1 after 300 
minutes is not known. The polydispersity index also changed over time. At the start of the 
experiments it was 0.29, but after 300 min, it was 0.43. The polydispersity was at its 
highest after 150 minutes, with a value of 1. It is important to note that in polydisperse 
samples, which have a polydispersity index above 0.1, the reported particle sizes have 
large deviations. These data suggest that His-BD1 aggregated rapidly over time, and that 
after 300 minutes, a large aggregate with a diameter exceeding 1000 nm was formed. 
 
4.5.4 DLS also revealed aggregation of His-BD2  
His-BD2 showed no visible signs of aggregation in the form of precipitation after 
purification, but particle size measurements with DLS showed that His-BD2 was not 
present as an entirely monomeric protein. Three distinct peaks which correlate with the 
Figure 4.10: His-BD1 aggregation over time: Particle sizes were measured by DLS. A: The particle size 
distribution of a His-BD1 sample (245 µM) was monitored over time by 5 minute interval readings over 
a time course of 16 hours. Only the first 300 minutes are presented. B: The particle size distribution of 
the His-BD1 sample (245 µM) at the start of the experiment, 0 min, and after 300 minutes.  
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presence of three particle sizes were seen from DLS data of His-BD2 (Figure 4.11). The 
peak of the highest intensity was found to have a mean hydrodynamic particle diameter 
of 6.4 nm (Peak 1), while the second prominent peak indicates the presence of a larger 
particle with a mean diameter of approximately 100 nm (Peak 2). Furthermore, a wide 
peak is also present at around 1100 nm (Peak 3). The Pdi of the sample was 0.5. The 
estimated molecular weights of the peaks and a summary of the His-BD2 size distribution 
measurements is presented in table 4.2. The His-BD2 sample that was used for DLS 
measurements was not centrifuged before measurements were performed. This can 
explain the apparent higher intensity of the larger 100 nm peak compared to His-BD1 
which displayed stronger visual signs of aggregation. No time-course experiments were 
performed with His-BD2. The collected data suggested that there was some degree of 
aggregation into larger complexes in the case of His-BD2 as well. Due of the rapid 
aggregation observed with DLS, His-BD1 and His-BD2 samples were freshly purified 
immediately before ITC and SPR experiments, and kept at low concentrations. 
 
Table 4.2: Particle size distribution of His-BD2 
Peak Mean particle 
diameter* (nm) 




1 6.4  9.0 54.7 52.3 
2 96.3 3.7 37.7 78,866 
3 1136 0.5 7.6 Too large 
*Two times stokes radius 
+ 𝑟 = 0.483(𝑀𝑤)0.386 – r: Stokes radius (Å), Mw: Molecular weight (kDa) (Venturoli and Rippe, 2005) 
Figure 4.11: His-BD2 shows signs 
aggregation. Particle sizes were measured by 
DLS. Three independent readings of the 
particle size distribution of a His-BD2 sample 
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4.6 ITC with Brd4 bromodomains 
To validate the results acquired from histone peptide binding assays, which showed no 
binding between Brd4 bromodomains and H3K27ac, ITC measurements were performed. 
ITC was carried out with His-tagged Brd4 bromodomains and H3K27ac/H4tetra-ac 
peptides. Measurements with H4tetra-ac were included as a positive control. 
 
4.6.1 Brd4 BD1 shows no apparent binding to H3K27ac 
ITC experiments were performed with His-tagged BD1 purified by IMAC (Section 3.2.3). 
Since extensive and rapid aggregation was observed for His-BD1, ITC measurements were 
carried out directly after purification and dialysis, and the samples were centrifuged for 
20 minutes before use. Three independent experiments for His-BD1 binding to H4tetra-
ac were performed, but only two experiments were conducted for determining the 
binding to H3K27ac, as they showed negative results. ITC with His-BD1 and H4tetra-ac 
showed a typical pattern for binding reactions (Figure 4.12.A). Each peak represents one 
injection. The heat of dilution was measured in a separate experiment, by titrating 
H4tetra-ac into T7.5 buffer. The collected ITC data was fitted to a model for 1:1 binding 
(Figure 4.12.B). Models fitted to ITC data exhibiting binding are expected to have a 
sigmoidal shape. This was not the case for ITC experiments with His-BD1 and H4tetra-ac, 
as they lacked the lower plateau. The standard deviations of collected data points were 
large, which is most likely due to the instability of baseline which was observed for all ITC 
measurements with His-BD1 (Figure 4.12), and experiments done at longer intervals from 
purification had increasingly more unstable baselines, even after centrifugation of the 
proteins. Titrations of H4tetra-ac peptide in T7.5 and T8.5 buffer, however, showed a 
stable baseline with even peaks (Figure 4.12.B). Due to this, parameters calculated from 
the fitted model should be interpreted with care.  









A dissociation constant (KD) of 5.3 µM ± 0.33 and an n- value of 0.66 ± 0.11 were 
determined from the model of binding between His-BD1 and H4tetra-ac peptide. The n-
value gives the stoichiometry of the binding reaction, where a value of 1 indicates a 1:1 
binding.  
No typical binding pattern was observed in ITC experiments with His-BD1 and H3K27ac 
(Figure 4.12.C). The recorded heat rates are low, and equal the heat of dilution. No 
apparent binding between His-BD1 and H3K27ac can be seen from the curve. In 
experiments with H3K27ac a lower concentration of peptide was utilized. An initial 
experiment was done with 200 µM peptide and 20 µM protein, but this yielded low heat 
signals and the concentrations were raised to 0.79 mM H3K27ac peptide and 40 µM His-
BD1. After experiments with higher concentrations still gave no signals that indicated 
Figure 4.12: ITC of his-BD1 with H4tetAc and H3K27ac. ITC measurements were performed in a ITC 
Nano instrument from 20 titrations of 2.03 µl were introduced into the sample cell containing 300 µl 
His-BD1. A: 1.01 mM H4tetra-ac peptide titrated into 40 µM his-BD1. Each peak represents with one 
titration. B: Total heat of injection (µJ) of data shown in A, plotted as the area data of raw heat rate (µJ/s) 
against the mole ratio of H4tetra-ac to His-BD1. The error bars show the standard deviation between 
triplicates. The first data point has been removed, as it tends to give a low heat signal due to diffusion 
from the syringe as the system equilibrates before the first injection. The data have been fitted to a model 
assuming independent binding sites. C: 0.79 mM H3K27ac peptide titrated into 40 µM His-BD1, 150 mM 
NaCl D: 0.78 mM H3K27ac peptide titrated into 40 µM His-BD1, 300 mM NaCl. 
   4. Results 
56 
 
binding, it was deemed unnecessary to increase the concentrations further. An additional 
ITC experiment was performed with H3K27ac and His-BD1, with 300 mM NaCl rather 
than 150 mM NaCl (Figure 4.12.D). Earlier observations of the precipitation of His-BD1 
indicated that the domain possibly precipitated at a slower rate in a 300 mM NaCl buffer. 
However, no binding between His-BD1 and H3K27ac was observed under high salt 
conditions either, and the stability of the baseline was not increased. Interestingly, the 
baseline seemed to be more disturbed with a 300 mM buffer than with a 150 mM, and the 
heat rates were bigger. ITC experiments showed that His-BD1 binds H4tetra-ac, but not 
H3k27ac.  
 
4.6.2 His-BD2 shows no apparent binding to H3K27ac 
ITC experiments with His-BD2 were carried out in the exact same manner as for His-BD1, 
but a buffer with pH 8.5 was used due to its different pI value (Table 3.5). The ITC data of 
His-BD2 and H4tetra-ac showed a decrease in heat rate during H4tetra-ac titration, from 
0.6 µJ/s to around 0.2 µJ/s (Figure 4.13.A). Titrations of the same concentration of 
H4tetra-ac into T8.5 buffer showed the heat of H4tetra-ac dilution to be about 0.2 µJ/s per 
injection (Figure 4.13.B). This could indicate that there was some interaction occurring 
between H4tetra-ac and His-BD2, and as further injections of peptide were made, the 
system saturated. However, the injection peaks were uneven, and the baseline was 
disturbed which precluded fitting a model to the data. As depicted in the figure, some 
peaks have small bumps, which could be caused by heat being generated through domain-
domain interactions. These “bumps” increase the area under the peak, which causes the 
integrated data used for model-fitting to become inaccurate. Because of this, and the 
unevenness of the peaks themselves, the calculated area data does not form a sigmoidal 
pattern that could be modeled. The heat rates are also very low, making it harder to 
distinguish them from the baseline. Higher heat rates could be achieved by increasing 
peptide and protein concentrations further, but at 1 mM and 40 µM, the concentrations 
are already quite high. The ITC data of His-BD2 and H3K27ac showed no typical binding 
pattern, and a very disturbed baseline where the individual injections were hard to 
distinguish (Figure 4.13.C). No binding between His-BD2 and H3K27ac was indicated 
from the data. Table 4.3 summarizes the ITC results of His-tagged Brd4 BD1 and BD2 with 
H4tetra-ac and H3K27ac. 








Table 4.3: ITC of Brd4 bromodomains 
Domain Histone mark Protein1 (µM) Peptide2 (mM) n-value3 Kd (µM) 






0.66 ± 0.11 
- 
5.3 ± 0.31 
- 










1: Protein concentration in the sample cell before titration 
2: Peptide concentration in the syringe before titration 
3: The n-value gives the amount of binding sites per protein 
 
 
Figure 4.13: ITC of His-BD2 with H4tetAc and H3K27ac. 20 titrations of 2.03 µl were introduced into 
the sample cell containing 300 µl protein/buffer, with a stirring rate of 300 rpm.  A: 1.03 mM H4tetra-
ac peptide titrated into 43 µM His-BD2. Each peak represents one titration. B: 1.03 mM H4tetra-ac 
peptide titrated into T8.5 buffer. This shows the heat of dilution of H4tetra-ac in T8.5 buffer. C: 0.78 mM 
H3K27ac peptide titrated into 41 µM His-BD2. Note that the range of the y-axis does not correspond to 
figure 4.12. 




Differences between cell types arise from differences in their gene expression profiles. 
Enhancers are the major determinants differential gene expression and cell type 
specificity (Bulger and Groudine, 2010). They activate gene expression by bringing 
transcription factors and co-activators to the promoters they regulate. Genomic 
regulatory elements, like enhancers, have been shown to be enriched in specific 
combinations of histone PTMs, correlating to their state of activity. PTMs on histone tails 
can influence the regulation of genes through both disrupting nucleosome interactions 
and recruiting specific proteins that have roles in gene transcription (Ruthenburg et al., 
2007). Active enhancers are enriched with an acetylation mark on lysine 27 of histone H3 
(Creyghton et al., 2010). The role of this mark is not yet understood, but its enrichment at 
enhancers distinguishes active from primed and poised enhancers (Creyghton et al., 
2010). Histone PTMs are recognized by specialized reader domains, which in turn are part 
of or recruit proteins with different effector functions. Hence, the aim of this work has 
been to find a reader protein that specifically recognizes H3K27ac. 
In this project, Brd4, a bromodomain-containing protein previously shown to be involved 
in transcriptional elongation at both enhancers and promoters (Kanno et al., 2014), was 
investigated as a candidate protein for the specific recognition of the H3K27ac mark. BD1 
of Brd4 has earlier been reported to bind H3K27ac in a histone peptide SPOT array 
(Filippakopoulos et al., 2012).  H3K27ac and Brd4 have been found to co-localize in 
enhancer chromatin, and high levels of Brd4 are present at super-enhancers,  which also 
exhibit high levels of H3K27ac (Lovén et al., 2013). The co-localization of Brd4 and 
H3K27ac, combined with SPOT array data suggesting binding between the two, laid the 
basis of this work, where potential binding parameters were to be determined by means 
of histone peptide binding assays, SPR and ITC.   
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5.1 Histone peptide binding assays show no binding between Brd4 
bromodomains and H3K27ac 
An interaction between BD1 of Brd4 and H3K27ac had been previously observed in a 
SPOT- array assay where binding between 33 different human bromodomains and all 
possible single histone acetylation marks were investigated (Filippakopoulos et al., 2012). 
In this array, acetylated histone peptides with a length of 10-14 amino acids were 
synthesized directly on cellulose membranes. His-tagged bromodomains were incubated 
with the membrane, and after incubation, the bound domains were detected by 
immunoblotting with anti-His antibodies. Weak binding between BD1 and H3K27ac 
peptide was detected in one of these binding assays, while another assay detected a strong 
binding (Filippakopoulos et al., 2012).  
The objective of this project was to confirm the binding between Brd4 BD1 and H3K27ac 
with more quantitative methods, in order to lay the ground for future functional studies.  
First, histone peptide binding assays were performed; a method similar to the SPOT array 
assays used by Filippakopoulos et al. (2012). Histone peptide binding assays were carried 
out with GST-fusion Brd4 bromodomains and a panel of synthetic, biotinylated, modified 
and non-modified histone peptides. Our results showed, however, no significant binding 
between GST-BD1 or –BD2 and the H3K27ac peptide (Figure 4.5 A and B). Weak signals 
were detected for GST-BD1 with H3K27ac, but signals of similar intensities were observed 
with the negative controls as well, indicating that this was most likely due to unspecific 
interactions between GST-fusion proteins and the peptide, or between the proteins and 
the Sepharose beads. Interactions between GST-BD1 and Sepharose beads were detected 
in one out of three replicates that included this control.  
Strong binding between the H4tetra-ac peptide and GST-BD1 was, observed in all 
replicates, indicating that the domain was functional with capacity to bind other 
acetylated lysines. Strong binding between H4tetra-ac and GST-BD2 on the other hand 
was only observed in 1 out of 4 replicates, with large differences in the detected signal 
intensities. The reason for these large differences is unknown, but was most likely due to 
technical variations. Previous measurements of the interaction between BD2 of Brd4 and 
H4tetra-ac peptide by ITC gave a KD of 26.6 µM for this interaction (Filippakopoulos et al., 
2012). In comparison, the same study found a KD of 2.8 µM for BD1 binding to H4tetra-ac. 
   5. Discussion 
60 
 
This suggests that our assay may not have been sufficiently sensitive to detect a low 
affinity interaction between the Brd4 bromodomains and H3K27ac. Our histone peptide 
binding assays were apparently also prone to signals caused by unspecific binding, as 
pulldown of GST by different peptides was observed in several replicates. As we observed 
non-specific binding in our initial histone peptide binding assays, we reduced the 
concentration of bromodomains in our experiments. While a lower concentration of 
protein in these experiments may have increased the specificity in the assay, it may also 
have lowered the sensitivity.  
Bromodomains have been shown to bind with higher affinity to histone peptides that have 
two acetyl-lysines separated by 2-5 amino acids (Morinière et al., 2009). In light of this, a 
di-acetylated peptide  (H3K23,K27ac) was also included in the assay. However, no binding 
was observed between H3K23,K27ac and the Brd4 bromodomains. It has been reported 
that the number and types of amino acids that separate acetylated lysines affect the 
binding-specificity of Brd4 BD1 (Filippakopoulos et al., 2012). BD1 was found to prefer 
acetylated lysines separated by the sequence “GG”, as is found between H4 K5 and K8. 
Positive residues in the sequence were found to diminish binding. The amino acid 
sequence between H3 K23 and K27 is “AAR”, which could explain the lack of binding 
observed in our assays. Interestingly, none of the lysines of H3 are separated by linker 
sequences optimal for BD1- binding. Binding by BD2 is less affected by the length and 
composition of the linker region. 
 
5.2 Lack of binding between Brd4 bromodomains and H3K27 is 
confirmed by ITC 
After our initial histone peptide binding assays indicated that none of the Brd4 
bromodomains bind the H3K27ac peptides, we wished to confirm these results by the use 
of ITC. The molecular interaction between two molecules, at equilibrium in solution, can 
be measured by ITC. The measurement of heat transfer during binding enables 
determination of binding constants (KD), reaction stoichiometry (n), enthalpy and 
entropy. These parameters give a good biophysical characterization of the binding 
reaction. In this work, ITC measurements were carried out with His-tagged Brd4 
bromodomains and H3K27ac and H4tetra-ac peptides. No apparent binding was observed 
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between either of the two Brd4 bromodomains and H3K27ac, confirming the 
observations made from histone peptide binding assays. There were however difficulties 
with these measurements, as is discussed below. 
 
5.3 His-BD1 binds H4tetra-ac peptide, but not in a simple 1:1 
relationship 
Measurements with ITC showed binding between His-BD1 and H4tetra-ac with a KD of 5.3 
± 0.31µM. Previous studies have found an affinity of 2.8 µM using ITC (Filippakopoulos et 
al.,2012), and 2.4  µM using SPR (Jung et al., 2014), for this interaction. Fitting the data for 
binding between His-BD1 and H4tetra-ac to a binding model for independent binding 
sites resulted in a binding curve that lacked the lower plateau of a typical sigmoidal 
binding model. This is most probably due to the large difference in concentration between 
His-BD1 and H4tetra-ac peptide. This large concentration difference was used because 
bromodomains are reported to have low affinities for their acetyl-lysine ligands, which 
requires that high peptide concentrations are needed for ITC experiments.  
 A stoichiometry (n-value) of 0.66± 0.11 was calculated from the three ITC replicates of 
binding between His-BD1 and H4tetra-ac. The n-value represents the number of binding 
sites on the protein, and a value below 1 could indicate that several domains are binding 
the same peptide. Aggregation of domains can cause changes in the estimated n-value of 
a binding reaction, which is likely to be the case for ITC with His-BD1. Interestingly, an n-
value of 0.57 for the binding between BD1 and H4tetra-ac has previously been reported, 
suggesting that the binding mechanism might not be a simple 1:1 binding 
(Filippakopoulos et al. 2012). A stoichiometry value of  0.5 has also been reported for 
binding of both BD1 and BD2 of several BET-family proteins to H4 peptides acetylated at 
three or more positions (Filippakopoulos et al., 2012). This could indicate that two 
bromodomains bind to each H4tera-ac peptide, perhaps binding two acetyl-lysines each, 
as is the case for other bromodomains (Morinière et al., 2009). The dimensions of the 
bromodomains and pairs of acetylated lysines on the tetra-acetylated histone H4 tail are 
compatible with a model where two bromodomains can bind simultaneously to one and 
the same histone tail (R. Aasland, pers. comm). In addition, Brd4 BD1 was shown to have 
higher affinity for H4 histone peptides acetylated at four positions (K5,8,12,16) than for 
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di-acetylated peptides (H4K5,8ac, H4K8,12ac or H4K12,16ac) (Filippakopoulos et al., 
2012). This could indicate that two bromodomains bind to the tetra-acetylated peptide. It 
is important to keep in mind that these studies were done with free bromodomains, and 
out of context to the full-length Brd4 protein. 
 
5.4 His-BD2 shows weak binding to H4tetra-ac  
ITC with His-BD2 and H4tetra-ac showed signs of weak binding, in the form of heat signals 
that decreased as more peptide was titrated into the sample cell.  When compared to ITC 
with His-BD2 and H3K27ac (Figure 4.13 A and C), which in this context can serve as a 
negative control, there is a large difference in the pattern of heat rates. However, the 
baseline of His-BD2 ITC data was very unstable, and large “bumps” that can be seen close 
to the injection peaks cause the area data to increase. These “bumps” are most likely due 
to domain-domain interactions in the sample caused by aggregation. The increase in area 
under the peaks, combined with the unevenness of the peaks themselves made modeling 
of the data difficult. Hence no quantitative calculations could be made.  Earlier ITC 
experiments of the binding between BD2 and H4tera-ac found an affinity of 26.6 µM 
(Filippakopoulos et al., 2012). These experiments, however, used peptide concentrations 
of 1.5 mM and protein concentrations of 50 µM, whereas our experiments were carried 
out with 1 mM H4tetra-ac peptide and 40 µM His-BD2. The higher concentrations of 
peptide and protein in these experiments can explain why the binding could be quantified 
in these experiments, but not in ours. 
 
5.5 Aggregation of His-tagged bromodomains interfered with ITC  
Studies of the oligomeric states of His-BD1 and BD2 with SEC and DLS showed that these 
domains formed large aggregates shortly after purification. Time course experiments of 
the size distribution of His-BD1 by DLS showed that it aggregated rapidly, first to a 
particle with a diameter of 164 nm, and then further into even larger complexes with a 
hydrodynamic diameter that exceeded 1000 nm. Based on the relation between molecular 
weight and hydrodynamic radius (Stokes-Einstein radius), the most prominent peak 
(peak 1 figure 4.9.A) of His-BD1 was estimated to be 40-52 kDa, while the most prominent 
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peak in His-BD2 was found to be 52 kDa. Lysozyme (13.7 kDa) was by the same method, 
estimated to be 27.5 kDa. Many factors, including protein concentration, the ionic strength 
of the solvent and the polydispersity of the sample, can influence the apparent particle 
diameter in DLS measurements. This value can therefore be considered to be an 
overestimate. This is supported by data from size exclusion chromatography (SEC) which 
showed that the major molecule in the His-BD1 sample has a molecular weight of ~13 
kDa. This is close to the theoretical molecular weight of His-BD1 (16.3 kDa). Hence, the 
SEC data suggest that most of the His-BD1 is a monomer in solution. Analysis of the His-
BD1 and His-BD2 samples by DLS showed a high degree of polydispersity (PD index= 0.3) 
and made the analysis of particle sizes in these samples difficult. DLS time course data of 
His-BD1 showed that larger particles were forming, and confirmed that aggregation was 
occurring rapidly. Particle size distribution measurements were done in T7.5 buffer, the 
same buffer used for ITC, at a protein concentration of 214 µM. In ITC experiments, the 
concentration of His-BD1 and His-BD2 was much lower, at 40 µM, so the rate of 
aggregation estimated from DLS is not directly applicable. However, the ITC data for His- 
BD1 and His-BD2 with acetylated histone peptides (Figures 4.12 and 4.13) showed signs 
of heat-generating interactions that were independent of the titration of peptide into the 
sample cell. This may be an indication that aggregation was occurring during the 
experiment. This effect was even more pronounced in experiments with His-BD1 or His-
BD2 and H3K27ac peptide, where distinguishing the individual peaks following injections 
was difficult. The aggregation of His-BD1 in ITC experiments with H4tera-ac resulted in 
an unstable baseline, which propagated into the modeled area data and caused large 
deviations in the upper plateau of the sigmoidal curve. This lead to a high degree of 
uncertainty when the data were fitted to the model, hence, the calculated binding 
parameters should be interpreted with care.   
 
5.6 Comparison to other binding studies with Brd4 bromodomains  
Our experiments with both histone peptide binding assays and ITC showed no binding 
between Brd4 bromodomains and H3K27ac peptide in vitro. This was contrary to 
previously published data which suggested binding between Brd4 BD1 and H3K27ac 
(Filippakopoulos et al., 2012). The SPOT assay performed in this study is however a large 
array where many bromodomains and peptides were screened for binding, and it is likely 
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that false positives occur in this type of assay. A particular problem in such a high-
throughput experiment is that the quality and oligomeric state of each of the proteins may 
not have been properly monitored. The Brd4 bromodomains utilized in the SPOT assays 
had the same amino acid sequences as our own (Figure 4.1), but were not reported to 
aggregate. The data presented here is a strong indication that the data from the SPOT 
assays must be interpreted with care. 
A recent study by Jung et al. (2014) showed similar results to ours, where lack of binding 
between Brd4 bromodomains and H3K27ac was observed using time-resolved 
fluorescence resonance energy transfer (TR-FRET) (Jung et al., 2014). Even though none 
of the Brd4 bromodomains showed binding to H3K27ac peptides in vitro in our 
experiments, this might not be directly applicable to a biological setting.  
 
5.7 The role of Brd4 at enhancer and promoter elements 
As our results showed that none of the bromodomains of Brd4 bind H3K27ac in vitro, the 
role of Brd4 as a specific H3K27ac-binder in enhancer chromatin must be reconsidered. 
Previous studies have shown that Brd4 occupancy at enhancers is dependent on its 
bromodomains, as inhibition with JQ1, a specific BET bromodomain inhibitor, prevents 
binding of Brd4 to enhancer chromatin (Kanno et al., 2014; Lovén et al., 2013). Brd4 is 
involved in the regulation of transcription elongation at both promoters and enhancers, 
and has been shown to mediate eRNA transcription at several active enhancers (Kanno et 
al., 2014; Lovén et al., 2013; Nagarajan et al., 2014). This action might however not be 
dependent on recruitment of Brd4 to enhancers through binding to H3K27ac.  
Our results showed that none of the bromodomains of Brd4 isolated from the full-length 
protein bind H3K27ac peptides in vitro. The affinity of Brd4 to H3K27ac in living cells 
might be regulated by the presence of other factors. Many bromodomains show low 
affinities for acetylated histone peptides in vitro, and it is possible that additional factors 
might contribute to binding in vivo. The presence of other nearby marks, such as 
phosphorylation and methylation has also been reported to affect the affinity of 
bromodomains to their targets (Filippakopoulos et al., 2012). The two bromodomains of 
Brd4 might work together or interact with each other in ways that could affect the 
protein’s affinity for specific or combination of acetylation marks. Other regions of Brd4 
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have been shown to influence its affinity for acetylated chromatin. The NPS-region 
immediately C-terminal of BD2 (Refer to figure 1.5) can bind BD2 when not 
phosphorylated, and prevents BD2 from interacting with acetylated chromatin (Wu et al., 
2013). Phosphorylation of this region by casein kinase II unmasks BD2 and allows Brd4 
to be recruited to acetylated chromatin. Phosphorylation of NPS also allows binding to the 
transcription factor p53, and subsequent Brd4-mediated recruitment of p53 to target 
genes and activation of transcription. When Brd4 binds to and cooperates with p53, it 
takes on a gene-specific regulatory function (Wu et al., 2013). 
In recent mass spectroscopy-coupled ChIP experiments, Brd4 was found to be the protein 
with the highest correlation with H3K27ac in the genome, and was found to be especially 
predominant at active enhancers (Engelen et al., 2015). These experiments did, however, 
use an extended cross-linking procedure, which could allow for detection of protein 
complexes. Co-localization of Brd4 and H3K27ac in chromatin does, however, not 
necessarily mean that Brd4 or its bromodomains are responsible for binding this mark.  
H3K27ac is also not the only acetylation mark present at enhancers, H3K9ac and H3K14ac 
have also been detected near active enhancers in nine human cell types (H3K9ac) and in 
mouse embryonic stem cells (H3K9ac and H3K14ac) (Ernst et al., 2011; Karmodiya et al., 
2012). It is possible that Brd4 is recruited to enhancer chromatin by binding to other 
acetyl-lysines in the histone tails, or to acetylated transcription factors. Brd4 has been 
reported to bind acetylated RelA, a subunit of the transcription factor NFkB through its 
bromodomains (Carlin et al., 2012). Interactions between the Brd4 bromodomains and 
transcription factor TWIST have also been reported (Shi et al., 2014). Brd4 might be 
present in a larger complex of proteins, where other proteins are responsible for the 
recognition of H3K27ac, and thus the recruitment to active enhancers.  
Recent studies have suggested that Brd4 acts as a histone chaperone that assists Pol II 
elongation through hyper-acetylated chromatin (Kanno et al., 2014). In this study, Brd4 
allowed transcription of Pol II through hyper-acetylated nucleosomes in a defined in vitro 
assay which was performed in the absence of P-TEFb. This action of Brd4 was suggested 
to occur at both promoters and enhancers. This could suggest that Brd4 can regulate 
transcription independently from P-TEFb and the methyltransferase NSD3 (Rahman et 
al., 2011). 
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After the start of this project, the YEATS domain of human AF9, a subunit of the super 
elongation complex, was found to bind H3K9ac, H3K18ac and H3K27ac with high affinity 
(Li et al., 2014).  The affinity of the YEATS domain for its acetylated targets is higher than 
that of many bromodomains (Filippakopoulos et al., 2012), which makes it a very 
interesting candidate for the specific recognition of H3K27ac. Brd4 and AF9 have both  
been reported to interact with the elongation factor P-TEFb, and it has been suggested 
that they also both bind and act as transcriptional co-activators of nuclear retinoid 
receptors (Flajollet et al., 2013). So far, no direct interaction between Brd4 and AF9 has 
reported.  
 
5.8 Future perspectives 
In this study, binding between transcriptional regulator Brd4, and H3K27ac, a histone 
modification enriched in active enhancers, was investigated. In our binding assays, which 
included histone peptide binding assays and ITC, no interaction was observed between 
either of the acetyl-lysine- binding bromodomains of Brd4 and H3K27ac histone peptides. 
These assays were, however, performed with single bromodomains, and several 
difficulties arose during the experiments. GST-fusion protein showed high background 
binding, and His-tagged bromodomains used for ITC measurements were found to 
aggregate. 
In future work, creating new and more soluble constructs would greatly improve the 
quantitative measurements of binding. In addition, investigation of binding with full-
length Brd4, or with protein constructs containing both bromodomains could yield more 
information of a possible binding between Brd4 and H3K27ac. Also, the chromatin context 
might play a role in “reader” protein binding, hence using nucleosome arrays as a 
substrate in binding experiments is advisable.  
Even though the investigation of possible binding between Brd4 and H3K27ac can be 
expanded, it would be of interest to find other binding candidates for the recognition of 
H3K27ac and determine their role in enhancer-promoter communication. The YEATS 
domain- containing protein AF9, or the three other human YEATS proteins are good 
choices for candidate proteins, as the YEATS domain has been shown to bind H3K27ac 
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with high affinity (Li et al., 2014). Some PHD-fingers have also been reported to bind 
acetylated lysines (Ali et al., 2012) and could be investigated as candidates. 
Pull-down experiments from nuclear extracts with H3K27ac peptides or recombinant 
nucleosomes carrying H3K27ac (Nguyen et al., 2014) followed by mass spectrometry 
would be one way to search for the true H3K27ac binders. Such experiments are in 
progress in our laboratory using an approach based on stable isotope labeling of amino 
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